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SUMMARY 
 
Background. The seronegative spondyloarthritis (SpA) are a group of chronic 
inflammatory diseases resulting from a complex interplay among genetic background 
(mainly represented by HLA-B27) and environmental factors, that leads to the 
activation of autoinflammation and the dysregulation of the immune-system.  
 In many cases, an early diagnosis and an appropriate monitoring of disease activity 
can be difficult because of the overlap of clinical features. Furthermore, because of the 
indices of inflammation, erythrocyte sedimentation rate (ESR) and C-reactive protein 
(CRP), are in the normal range in at least half of SpA patients with a clear expression of 
disease activity, a delay in diagnosis and consequently in treatment in these patients has 
been documented. This imparts a tremendous symptomatic burden and loss of function 
in these patients during the productive years of life. For all these reasons, much 
attention is currently devoted to the identification of biochemical and genetic 
biomarkers to be used in the diagnosis as well as prognostic factors in evaluating the 
treatment effectiveness.  
 Among the genetic predisposing factors, a well-known role is that of HLA-B27, 
which contributes however to only 20–30% of the total heritability, whereas the whole 
major histocompatibility complex (MHC) accounts for about 40–50% of the genetic 
risk of developing SpA. This suggested that other genes are involved in pathogenetic 
mechanism. In fact, in addition to HLA-B27, a number of genetic factors in both, MHC 
and non-MHC locus, have been claimed to play a role in pathogenesis of SpA.   
 In this context, because of TNF-α is primarily involved in the propagation and 
perpetuation of inflammation in SpA, the study of TNF-α genetic is of great interest. 
Several polymorphisms (SNPs) in genes involved in TNF-α signalling, as TNFA, 
TNFSF15, TNFR1 and TRADD genes, have been identified as associated with SpA, 
even if results are controversial. Of great interest are also variants in MEFV gene, 
involved in the pathogenesis of the autoinflammatory disorder Familial Mediterranean 
Fever (FMF). Recent studies have shown that the SpA, and in particular the ankylosing 
spondylitis (AS), are very common among patients affected by FMF and that these 
patients can present with AS as a sole manifestation.  
 The present study, conducted in a cohort of 91 SpA patients and 223 controls, 
coming from a North-East Italian region, was aimed to identify biohumoral 
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(biochemical and haematological) and genetic factors to support the diagnostic and 
prognostic (response to therapy) work-up of SpA diseases. In particular, in addition to 
biochemical and haematological indices, we investigated whether SNPs in the promoter 
region of TNFA, or SNPs in the autoinflammatory TNFRSF1A and MEFV genes, 
might concur with HLA-B27 in enhancing the risk of developing SpA disease and/or in 
predicting the response to anti-TNFα drugs.  
Methods. The study population comprised 91 patients with a diagnosis of SpA (mean 
age ± standard deviation: 52.1 ± 12.5 years; 57 males, 34 females) and 223 blood 
donors (mean age ± standard deviation:  46 ± 11 years; 146 males, 77 females) coming 
from Veneto Region, a North-East Italian region. Among patients, 36 had a diagnosis of 
AS and 55 patients of psoriatic arthritis (PsA), which were based on New York and 
CASPAR criteria respectively. The protocol of this study was approved by the Local 
Institutional Ethic Committee of University-Hospital of Padua, Italy (Prot.n. 3024P/13), 
and all participants gave written informed consent before entering the study.  
Demographic and physiological data, medical and familial history data were 
collected for each participant. Blood samples were collected and complete blood count, 
CRP, ESR, uric acid, prealbumin, alanina aminotransferase (ALT) and glucose were 
evaluated.  
Direct sequencing of MEFV (exons 2,3,5 and 10) and TNFRSF1A (exons 2,3,4 
and 6) genes were performed. HLA-B27 and TNFA polymorphisms (-1031T>C;-
857C>T;-376G>A;-308G>A;-238G>A) were assayed by Real Time-PCR. HLA-CW6 
allele presence was analysed by molecular genetic testing using a commercially 
available CE-IVD microarray. Statistical analysis was performed using STATA 
software (version 13.1).  
Results. An higher number of circulating polymorphonuclear cells and higher CRP 
levels could be detected in SpA patients with respect to controls, and in PsA higher 
levels of ALT could be observed with respect not only to controls but also to AS. 
Anyway these indices were not highly elevated and often comprised within the 
reference intervals.  
As expected, HLA-B27 was associated with AS (χ2=120.1; p<0.0001). Although 
a slightly higher frequency of HLA-CW6 carriers was observed among patients with AS 
(about 6%) or PsA (about 13%) with respect to controls (about 4%), the difference was 
not statistically significant. 
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Any single studied TNFA SNP was not associated with SpA diagnosis, nor with 
AS or PsA considered singly. The haplotypes deriving from the pairwise combinations 
of the five studied SNPs were also statistically inferred. The most frequent haplotypes 
in controls were selected as references, and only the haplotype -1031C/-308G was 
significantly associated with AS (p=0.015) exerting in this disease a protective role 
(Odds Ratio: 0.43; Confidence Interval 95%: 0.22-0.85).  
Three SNPs were identified in TNFRSF1A gene and among them, only the 
R92Q (Minor Allele Frequency- MAF=0.034) and the c.625+10A>G (MAF=0.479) 
were selected for their potential functional implications. Both SNPs were not associated 
with the presence of SpA (χ2=1.073 and p=0.300 for R92Q; χ2=4.721 and p=0.094 for 
c.625+10A>G), but c.625+10A>G was associated with the response to anti-TNF 
therapy, assessed by BASDAI score lower /equal or higher than 4 at 10 months 
(p=0.031).  
Twenty-one SNPs were identified in MEFV gene and among them, 10 with a 
known potential functional significance. Variant alleles were extremely rare in our 
population (MAF<0.025) except for R202Q (MAF=0.27). None was associated with 
SpA diagnosis (p>0.05).  
Conclusions. In conclusion the results of this study indicate the relevant role of TNF-
TNFR pathway genetics in the complex network causing SpA and conditioning 
response to therapy. TNFA was shown to be a predisposing factor for SpA, but mainly 
for AS, among Italian patients, while genetics of the autoinflammatory gene MEFV 
appears of no impact in this setting. The haplotype resulting from TNFA-1031C/-308G, 
potentially associated with lower TNF-α production, exerts a protective role in AS, 
while the TNFRSF1A c.625+10A>G polymorphism emerged as a potential predictor of 
response to anti- TNFα therapy.  
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RIASSUNTO 
 
Introduzione. Le spondiloartriti sieronegative (SpA) sono un gruppo di malattie 
infiammatorie croniche risultanti da una complessa interazione tra fattori genetici (tra 
cui, HLA-B27 è il maggior predisponente) e ambientali. Ed è tale interazione ad indurre 
l'attivazione di processi autoinfiammatori e la disregolazione del sistema immunitario 
caratterizzanti la malattia. 
In molti casi, una diagnosi precoce ed un adeguato monitoraggio dell’ attività di 
malattia risultano difficili a causa della sovrapposizione delle caratteristiche cliniche tra 
le diverse forme. Il ritardo nella diagnosi e conseguentemente nel trattamento, è inoltre 
dovuto al fatto che, gli indici d’infiammazione comunemente utilizzati nella pratica 
clinica, la velocità di eritrosedimentazione (VES) ed la proteina C-reattiva (PCR), sono 
nella norma in almeno metà dei pazienti con chiara espressione dell’attività di malattia. 
Il ritardo nella diagnosi conferisce a questi pazienti un carico sintomatico importante ed 
una perdita di funzione durante gli anni di vita produttiva. Pertanto, forte attenzione è 
attualmente rivolta all’identificazione di marcatori biochimici e genetici utili alla 
diagnosi e di fattori prognostici necessari a valutare l'efficacia del trattamento. 
Tra i fattori genetici predisponenti, è noto il ruolo di HLA-B27, che contribuisce 
però solo per il 20-30% all'ereditarietà totale, mentre il complesso maggiore di 
istocompatibilità (MHC) rappresenta circa il 40-50% del rischio genetico di sviluppare 
la patologia. Questo dato ha suggerito il probabile coinvolgimento di altri geni nel 
meccanismo patogenetico. Studi di associazione genetica hanno permesso di 
identificare un certo numero di altri geni, associati alla patologia, sia nel locus MHC 
che in altri loci.  
In questo contesto, di grande interesse è lo studio della genetica di TNF-α, 
considerato il ruolo di tale citochina nel propagare e perdurare dell'infiammazione. 
Sebbene numerosi studi abbiano dimostrato l’associazione tra i polimorfismi di geni 
coinvolti nella via del segnale del TNF-α (es. TNFA, TNFSF15, TNFR1 e TRADD) e la 
patologia di SpA, i risultati sono discordanti. Di grande interesse sono anche le varianti 
del MEFV gene, coinvolto nella patogenesi della malattia autoinfiammatoria Febbre 
Mediterranea Familiare (FMF). Studi recenti hanno, infatti, dimostrato che le SpA, ed in 
particolare la spondilite anchilosante (AS), sono molto comuni tra i pazienti affetti da 
FMF e che questi pazienti possono presentarsi con AS come unica manifestazione. 
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 Questo studio, condotto su 91 pazienti e 223 controlli, provenienti da una regione 
italiana del Nord-Est, si propone di identificare fattori bioumorali (biochimici ed 
ematologici) e genetici al fine di supportare i processi diagnostici e prognostici (risposta 
alla terapia). In particolare, oltre ai parametri biochimici ed ematologici, è stato valutato 
se polimorfismi nella regione del promotore del gene TNFA, o dei geni TNFRSF1A e 
MEFV, possano concorrere con l’allele HLA-B27 all’aumento del rischio di sviluppare 
la malattia e/o nel predire la risposta agli inibitori del TNF-α. 
Metodi. La popolazione studiata comprendeva 91 pazienti con diagnosi di SpA (età 
media ± deviazione standard:  52.1 ± 12.5 anni; 57 maschi, 34 femmine) e 223 donatori 
di sangue (età media ± deviazione standard: 46 ± 11 anni; 146 maschi, 77 femmine) 
provenienti dalla Regione Veneto, una regione italiana del Nord-Est. Tra i pazienti, 36 
presentavano AS e 55 artrite psoriasica (PsA), con diagnosi formulata sulla base dei 
criteri rispettivamente di New York e CASPAR. Il protocollo di questo studio è stato 
approvato dal Comitato Etico Istituzionale locale dell’Università-Azienda Ospedaliera 
di Padova, Italia (Prot.n. 3024P / 13), e tutti i soggetti arruolati hanno firmato un 
consenso informato prima di partecipare allo studio. 
Per ciascun soggetto arruolato, sono stati raccolti i dati demografici e fisiologici, 
la storia clinica e familiare. Sono stati raccolti poi, campioni di sangue, al fine di 
valutare l’emocromo e la VES, e di determinare i livelli di PCR, acido urico, 
prealbumina, alanina aminotransferasi (ALT) e glucosio. 
L’analisi molecolare dei geni MEFV (esoni 2,3,5 e 10) e TNFRSF1A (esoni 
2,3,4 e 6) è avvenuta mediante sequenziamento diretto. La determinazione degli alleli 
HLA-B27 e dei polimorfismi del gene TNFA (-1031T>C;-857C>T;-376G>A;-
308G>A;-238G>A) è stata condotta mediante PCR in Real-Time. La determinazione 
degli alleli HLA-CW6 è avvenuta mediante un test genetico molecolare CE-IVD, 
disponibile in commercio, che adotta la tecnologia microarray. L’analisi statistica è stata 
effettuata utilizzando il software STATA (versione 13.1).  
Risultati. Un maggior numero di cellule polimorfonucleate circolanti e livelli di PCR 
più elevati sono stati rilevati nei pazienti affetti da SpA rispetto ai controlli. Inoltre, i 
pazienti affetti da PsA hanno mostrato livelli più elevati di ALT, non solo rispetto ai 
controlli, ma anche rispetto a pazienti affetti da AS. In ogni caso tali indici non erano 
molto elevati e spesso risultavano compresi entro gli intervalli di riferimento. 
Come atteso, gli alleli HLA-B27 sono risultati associati all’AS (χ2=120.1; 
p<0.0001). Sebbene una frequenza leggermente maggiore degli alleli HLA-CW6 sia 
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stata osservata tra i pazienti con AS (circa il 6%) o PsA (circa il 13%) rispetto ai 
controlli (circa 4%), la differenza non è risultata essere statisticamente significativa. 
Nessuno dei polimorfismi del gene TNFA è risultato singolarmente associato 
alla diagnosi SpA, né a quella di AS o PsA, se valutate indipendentemente. Sono stati, 
poi, statisticamente dedotti gli aplotipi derivanti dalle coppie di combinazioni dei cinque 
polimorfismi studiati. Gli aplotipi più frequenti nei controlli sono stati selezionati come 
aplotipi di riferimento, e solo l’aplotipo -1031C/-308G è risultato significativamente 
associato con l’AS (p=0.015) esercitando in questa malattia un ruolo protettivo (odds 
ratio: 0.43; intervallo di confidenza al 95%: 0.22- 0.85).	  	  
Tre polimorfismi sono stati identificati nel gene TNFRSF1A e tra questi, solo i 
polimorfismi R92Q (Frequenza dell’allele minore- MAF = 0.034) e c.625 + 10A> G 
(MAF = 0.479) sono stati selezionati a causa del potenziale ruolo funzionale. Entrambi i 
polimorfismi non sono risultati associati con la diagnosi di SpA (χ2 = 1.073 e p = 0.300 
per R92Q; χ2 = 4.721 e p = 0.094 per c.625 + 10A> G). Il polimorfismo c.625 + 10A> 
G è però, risultato essere associato con la risposta alla terapia con anti-TNF, valutato 
sulla base di un punteggio BASDAI inferiore / uguale o superiore a 4, a 10 mesi 
dall’inizio della terapia (p = 0.031). 
Ventuno polimorfismi sono stati identificati nel gene MEFV e tra questi, 10 noti 
per il potenziale significato funzionale. Tali varianti alleliche sono risultate 
estremamente rare nella nostra popolazione (MAF <0.025) ad eccezione di R202Q 
(MAF = 0.27). Nessun polimorfismo è risultato essere associato con la diagnosi SpA 
(p> 0.05). 
Conclusioni. In conclusione, i risultati di questo studio suggeriscono il ruolo rilevante 
della genetica della via del segnale TNF-TNFR nel complesso sistema che induce la 
patogenesi di SpA e condiziona la risposta alla terapia. Il gene TNFA, nella popolazione 
oggetto di studio, si è dimostrato un fattore predisponente per lo sviluppo di SpA, ma 
soprattutto di AS. Al contrario, la genetica del gene MEFV non sembra mostrare alcun 
impatto in questo gruppo di malattie. L'aplotipo TNFA-1031C/-308G, potenzialmente 
associato alla produzione di livelli più bassi di TNF-α, sembra esercitare un ruolo 
protettivo nella patogenesi di AS, mentre è emerso che il polimorfismo c.625 
TNFRSF1A + 10A> G costituisce un potenziale fattore predittivo di risposta alla terapia 
con anti-TNFα. 
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1. INTRODUCTION 
 
1.1 Spondyloarthritis 
In 1974, Moll and colleagues introduced the concept of seronegative spondarthritides, a 
group of chronic inflammatory diseases characterized by the sharing of genetic, clinical 
and radiological features, clearly different from the other rheumatic diseases.  
The term ‘seronegative’ referred to the absence of rheumatoid factor in serum, feature 
that allowed distinguishing these disorders from rheumatoid arthritis [1].  
The term ‘spondarthritides’ as well as ‘spondyloenthesiticarthropathies’, was used to 
highlight the three main aspects of these disorders: the inflammation of the axial 
skeleton (sacroiliac joints and spine); the inflammation at entheses (sites of attachment 
of tendon, ligament, fascia or joint capsule to bone); and less frequently, the peripheral 
arthritis, commonly occurring in a characteristic pattern, asymmetric, oligoarticular and 
preferentially in the lower extremities. Today, the term ‘spondyloarthritis’ (SpA) is 
preferable to ‘spondyloarthropathy’, to better emphasize the inflammatory nature of 
these diseases [2,3].  
Extra-articular features, such as cutaneous (psoriasis, pustular lesions, erythema 
nodosum, pyoderma gangrenosum), ocular (uveitis) and mucosal (oral, intestinal, 
genital ulcers) manifestations as well as the inflammatory bowel disease (IBD) are also 
present [2-4].  
Furthermore, characteristic features of SpA family are the strong association with the 
human leukocyte antigen (HLA) B27 gene and the frequent familiar linkage.  
The understanding of genetics, pathophysiology of inflammation (e.g., lesions on 
Magnetic Resonance Imaging- MRI), and structural damage (e.g., sacroiliitis on plain 
radiographs) affect clinical practice in the context of classification and diagnosis. Based 
on the specific pattern, patients are classified as belonging to a specific subgroup [4].  
 
1.1.1 Classification criteria  
In many cases the classification in subgroups can be difficult because of the overlap of 
clinical features. In fact, in addition to a common genetic background, there is often an 
overlap of several symptoms among SpA family diseases, making difficult an early 
diagnosis in a patient showing clinical signs attributable to a SpA.  
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For this reason, over the years it became necessary to identify a standardized and 
evidence-based approach to classify these diseases.  
With the specific intention of classifying SpA including patients with undifferentiated 
spondylarthropathy (uSpA), in 1991, the European Spondyloarhropathy Study Group 
(ESSG), developed a set of classification criteria for the entire group of SpA (Figure 1) 
including inflammatory back pain and peripheral arthritis as major entry criteria.  
 
 
Figure 1. The ESSG criteria for the classification of SpA [5]. 
 
Five major subtypes of SpA are recognized on the basis of ESSG classification criteria: 
ankylosing spondylitis (AS), psoriatic arthritis (PsA), reactive arthritis (ReA), 
spondyloarthritis related to inflammatory bowel disease (IBD- SpA) and uSpA. The 
ESSG classification criteria for SpA have been well studied and validated in population 
studies and have a good sensitivity of 75% and a specificity of 87% [5]. 
Therefore, these criteria were not sufficient to classify patients with isolated clinical 
manifestations, such as peripheral arthritis, dactylitis, enthesitis, inflammatory back pain 
or acute anterior uveitis [4]. 
In the same period, Amor and colleagues proposed an alternative set of classification 
criteria, allowing a patient to be classified as having SpA whatever the presenting 
symptoms. The Amor criteria scores out of 12 features covering 4 domains: symptoms, 
radiographic and genetic features, response to treatment (Table 1). 
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Table 1. The Amor classification Criteria for SpA (modified by Amor et al, 1990) [6]. 
Amor classification criteria 
Clinical symptoms or past history of Score 
 1 Lumbar or dorsal pain at night or morning stiffness of lumbar or dorsal pain 1 
 2 Asymmetrical olygoarthritis 2 
 3 Buttock pain 1 
or 
2 
   
If Alternate buttock pain 
 4 Sausage-like toe or digit 2 
 5 Heel pain or other well defined enthesitis 2 
 6 Iritis 1 
 7 Non-gonococcal urethritis or cervicitis within one month before the onset of 
arthritis 
1 
 8 Acute diarrhea within one month before the onset arthritis 1 
 9 Psoriasis, balanitis, or inflammatory bowel disease (ulcerative colitis or 
Crohn’s disease) 
2 
Radiological findings  
 10 Sacroiliitis (bilateral grade 2 or Unilateral grade 3) 3 
Genetic background 
 11 Presence of HLA B27 and/or family history of ankylosing spondylitis, 
reactive arthritis, uveitis, psoriasis or IBD 
2 
Response to treatment 
 12 Clear-cut improvement within 48 hours after NSAIDs intake or rapid relapse 
of the pain after their discontinuation 
2 
A patient is considered as suffering from a spondyloarthropathy if the sum is ≥ 6 
 
These criteria, showed higher sensitivity (85%) and specificity (90%) than the previous 
model, thanks to the inclusion of ocular manifestations of dactylitis and positivity for 
HLA-B27 [6]. 
Both these set of criteria, were useful over the years in classification of SpA but not in 
everyday clinical practice, where it is necessary to include patients in earlier stages of 
the disease. The main limitation of ESSG criteria consists in the low sensitivity and 
specificity, that have shown if applied in the early stages of the disease (i.e. within 12 
months from onset of symptoms). 
With this motivation and recognising of the drawbacks of criteria focused on a specific 
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subtype the Assessment of SpondyloArthritis international Society (ASAS) has decided 
to continue the work of ESSG group to improve the current classification criteria for 
SpA. The ASAS did a large cross-sectional study to propose new criteria on the basis of 
the two main clinical features identified in daily practice: axial symptoms and 
peripheral involvement [7]. In fact, while some diseases within the SpA group affect the 
axial skeleton predominantly, some others involve the peripheral skeleton primarily.  
ASAS classification criteria for axial and peripheral SpA are shown in Figures 2 and 3, 
respectively. 
 
Figure 2. The ASAS classification Criteria for axial SpA [7].    
 
 
Figure 3. The ASAS classification Criteria for pheripheral SpA [7]. 
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The inclusion of the MRI among the ASAS classification criteria allowed identifying 
the signs of axial inflammation in the early stages of the disease. 
The advantage of this classification approaches is in a better representation of the 
disease at an early stage and improving the therapeutic choice, differing therapeutic 
strategies precisely according to the main axial or peripheral form. 
According to ASAS criteria, today, SpA are classified into two main groups: the first 
one represented by axial spondyloarthritis (axSpA) includes non-radiographic axial 
spondyloarthritis (nr-axSpA) and AS; and the second one, the peripheral 
spondyloarthritis (pSpA) including PsA, ReA, and IBD- SpA (Figure 4) [3].  
 
Figure 4. The Spectrum of SpA. The current concept [3]. 
 
1.1.2 Epidemiology of Spondyloarthritis  
A wide variation in the prevalence of SpA and its specific subgroups has already been 
described in literature. The differences have been mainly related to geographic area and 
in particular to genetic characteristics, first of all the presence of HLA-B27. Moreover, 
demographical and methodological difference between studies (mean age of the 
patients, male:female ratio, year of data collection, sampling design), other than 
different criteria used to diagnose SpA and classify subtypes can explain heterogeneity 
in estimated prevalence of SpA.  
Stolwijk and colleagues have recently published data concerning a meta-regression 
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analysis on the global prevalence of SpA. They reported a pooled prevalence of SpA 
ranging from 0.20% (95% Confidence Interval-CI: 0.00-0.66) in South-East Asia to 
1.61% (95% CI: 1.27-2.00) in Northern Arctic communities (Figure 5).  
 
 
Figure 5. The Global prevalence of SpA [8]. 
 
The estimated prevalence of AS, stratified by groups, ranged from 0.02% (95% CI: 
0.00-0.21) in Sub- Saharan Africa to 0.35% (95% CI: 0.24-0.48) in Northern Arctic 
communities; while the prevalence of PsA from 0.01% (95% CI: 0.00-0.17) in the 
Middle East to 0.19% (95% CI: 0.16-0.32) in Europe. Few data are available on the 
prevalence of other SpA subgroups, anyway generally low (ReA: 0.0-0.2%; IBD- SpA: 
0.0-0.1%, uSpA: 0.0-0.7%) [8]. 
In literature, is available only one study on the prevalence of SpA in Italy, conducted on 
2155 subjects coming from Marche, a region located in the centre of Italy. In this study, 
the most common SpA subsets were PsA, with a prevalence of 0.42% (95% CI: 0.31–
0.61), and AS with 0.37% (95% CI: 0.23–0.49). Two cases with uSpA, two with ReA, 
and two with IBD-SpA were also observed (0.09%, 95% CI: 0.04–0.16) [9]. 
 
1.1.3 Pathogenesis of Spondyloarthritis 
The onset of SpA typically occurs at a young age (<45 years, and usually between 20- 
40 years of age), but due to the lack of a pathognomonic clinical feature or laboratory 
test, early diagnosis is difficult. The average delay in diagnosis is estimated to be 8-11 
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years [10].  Without early diagnosis and with delayed treatment, SpA imparts a 
tremendous symptomatic burden and loss of function during the productive years of 
life.  
The delay in diagnosis, the inflammation indices in the normal range in at least half of 
SpA patients with a clear disease activity and the lack of complete clinical response to 
treatment have raised interest in the pathogenetic mechanism involved in the genesis of 
this group of diseases.  
Despite, the numerous studies available in literature, the pathogenesis of SpA is still not 
entirely clear. SpA are multifactorial diseases, that result of a complex interplay among 
an inherited genetic background (mainly represented by the HLA-B27 haplotype) and 
environmental factors (infections, mechanical stress, abnormal intestinal microbiota), 
that leads to the activation of autoinflammation and the dys-regulation of the immune-
system [2-4]. 
 
1.1.4 Diagnosis 
The wide variety of expression of these diseases is reflected in an equally variable 
spectrum of presentation, both from a clinical that biohumoral point of view.  
Laboratory  
 
As in rheumatoid arthritis and other inflammatory arthropathies, specific biomarkers of 
disease activity are not commonly used in clinical practice, because there is not a 
specific diagnostic biomarker.  
The absence of rheumatoid factor in serum is a typical feature of SpA patients 
distinguishing these disorders from rheumatoid arthritis. 
In the context of inflammatory spine symptoms, levels of acute phase reactants as C-
reactive protein (CRP) or erythrocyte sedimentation rate (ESR) can be higher in severe 
AS (40‐50% of patients) and acute exacerbations (notably ReA and PsA) than in those 
non-radiographic SpA, but at least half of patients with SpA presents indices of 
inflammation in the normal range, even in the presence of clear expression of disease 
activity with inflammatory synovial fluid, clinical pathologic expressions and 
radiographic signs, causing serious structural changes and damage involving the 
entheses, the peripheral joints, sacroiliac joints and column. Therefore, a normal ESR or 
CRP does not rule out this condition.  
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Where inflammatory disease is severe and prolonged, features of anaemia of chronic 
disease may be evident. Furthermore, persistently elevated serum immunoglobulin A 
(IgA) is a common, but non-specific finding. 
The presence of HLA-B27 increases the chance of ultimately diagnosing a SpA, but is 
not sufficient to diagnose the condition. In fact, although 85‐95% of white patients with 
AS has HLA‐B27, only 6% of HLA‐B27 carriers in the general population develop the 
condition. HLA-B27 is particularly useful for diagnosis of non-radiographic SpA [11].  
Imaging 
 
Although the diagnosis of SpA is based primarily on clinical manifestations, imaging 
techniques are fundamental to confirm the suspected diagnosis, to define the extent of 
disease and to monitor changes. 
Radiographs may be normal, even if there is a long history of suspiciously relevant 
(previously undiagnosed). In fact, conventional radiology can usually detect late-
alterations. In order to identify early-signs of enthesitis, it is necessary to resort to 
methods with higher sensitivity such as ultrasound combined with power Doppler and, 
above all, the MRI. 
Therefore, in SpA the development of sensitive and specific imaging or biological 
markers for early diagnosis remains one of the major challenges [11].  
 
1.1.5 Outcome Assessment 
In the context of the patient management, five questions concerning the possible clinical 
presentations (axial, peripheral, enthesopathy, and extra-articular) must be continuously 
assessed: does the patient really have the disease, is the disease active, is the disease 
severe, is the disease potentially severe, and is the disease refractory?  
Several outcome indexes are commonly used in daily practice and clinical trials to 
assess these domains [12]. 
Activity disease in SpA refers to the inflammation and is commonly assessed in daily 
practice with the bath ankylosing spondylitis disease activity index (BASDAI), a self- 
administered questionnaire. This index consists of questions related to the patient’s self-
assessment (e.g., fatigue, pain, swelling, axial and peripheral symptoms, enthesopathy, 
and duration and intensity of morning stiffness) [13,14].  
To improve the objective properties of such an index has been developed another 
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activity disease index, the ankylosing spondylitis disease activity score (ASDAS) 
questionnaire. This index includes other than the four questions from the BASDAI, also 
the level of acute phase reactants evaluation [15,16]. 
Furthermore, the peripheral joint commitment can be assessed through the count of 
tender/swollen joints and the evaluation of dactylitis and enthesitis indices, as the 
Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) [17] and Disease 
Activity Score- 28 (DAS-28) [18]. 
The spinal pain can be evaluated with a 10-cm visual analogue scale (VAS) and a visual 
analogue scale of global disease activity (VASg) [19, 20]. 
The severity of disease refers to structural damage, often due to tissue remodelling and 
its functional consequences. Because the structural damage and functional impairment 
in SpA are largely irreversible, it is necessary to predict the natural course of the disease 
at an early stage. 
In this context, several outcomes domains have been proposed to show severity: death, 
job loss, functional impairment, range of motion, and hip involvement.  
The Bath ankylosing spondylitis functional index (BASFI) [21] and the Health 
Assessment Questionnaire (HAQ) [22] assess the functional statement.  
The spine mobility can be investigated through the Bath Ankylosing Spondylitis 
Metrology Index (BASMI) [23].  
Furthermore, the outcome indexes are also important to lead the clinicians in the choice 
of treatments. In fact, whether the disease is refractory is important to move from a first-
line to a second-line treatment [4]. 
 
1.1.6 Treatment 
The objectives of treatment of SpA are to improve the condition of the patient (e.g., 
pain, functional disability) and to prevent subsequent clinical deterioration.  
Considered the variable spectrum of presentation of SpA, the therapy is usually based 
on the use of different treatment strategies depending on the main clinical 
manifestations. In general, non-pharmacological methods (physical and occupational 
therapy) are combined to drug therapies.  
Non-steroidal anti-inflammatory drugs (NSAIDs) represent the cornerstone of 
pharmacological therapy for SpA, especially for axSpA. In fact, NSAIDs rapidly (48–
72 h after intake) reduce pain and stiffness (reducing the level of acute-phase reactants) 
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and are effective on outcome measures.  
Despite the evidence of high rates of response with regard to the inflammatory spinal 
pain, approximately 50% of patients with early onset continue to have active disease. 
Furthermore, despite the benefits of the short-term therapy, the potential long-term 
gastrointestinal and cardiovascular toxic effects due to the daily intake of NSAIDs have 
to be taken in account in the choice of therapy [24]. 
Disease-modifying antirheumatic drugs (DMARDs) such as sulfasalazine, methotrexate, 
leflunomide and cyclosporine, effective in the treatment of peripheral arthritis and other 
extra- articular features such as psoriasis, uveitis, and inflammatory bowel disease, have 
no proven efficacy for either the axial or enthesopathic features of SpA.  
Therefore, the pharmacological therapy of SpA is generally based on the association of 
NSAIDs with DMARDs.  
The major clinical and therapeutic advance in SpA treatment is the successful use, in the 
last decade, of biological drugs and in particular of tumor necrosis factor α (TNF-α) 
inhibitors (etanercept, infliximab, adalimumab, golimumab, etc.) in active and 
refractory disease [25].  
The rational use of TNF-α inhibitors (anti- TNFα) is based on the pro-inflammatory 
effects of this cytokine implicated in the pathogenesis of several diseases, such as SpA, 
psoriasis, rheumatoid arthritis and inflammatory bowel diseases. Anti-TNF-α agents act 
by inhibiting the binding of TNF-α to its receptors and therefore interfere with TNF-α 
signaling transduction pathways. 
TNF-α inhibitors are highly effective in targeting the different disease features, not only 
axial disease but also peripheral arthritis, enthesitis, and extra-articular features such as 
psoriasis or uveitis [26]. Treatment with anti-TNFα drugs leads to a significant 
improvement in working life (employment, sick leave and productivity) and physical 
activity (participation rate, hours/week, and physical intensity) [27]. It also been proven 
that the effectiveness of TNF-α inhibitors is maintained for several years of treatment, 
and the different TNF-α inhibitors seem to show the same effect on different clinical 
manifestations [28]. 
Despite its major therapeutic effectiveness, a 20–40% of the patients do not respond 
well to treatment and the genetic background may play an important role in this context. 
In case of failure of a first TNF-α inhibitor, trying a second one is justified since many 
patients do still respond to a different anti-TNFα. Finally, although TNF-α inhibitors 
seem to halt joint destruction, they fail to slow new bone formation in SpA [29].   
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1.2 Ankylosing spondylitis 
Ankylosing spondylitis (AS) is the most prevalent subtype of axSpA with an overall 
estimated prevalence ranging from 0.1 to 1.4%, in Middle-Europe. The estimated 
incidence ranges from 0.5 to 1.4 per 100000 people per year in studies from different 
countries. AS generally affects young people aged from 20 and 40 years and less than 
5% of cases have an onset after 45 years. The male:female ratio is 3:1 and usually the 
clinical expression is more severe in males. AS is an inflammatory disease involving 
primarily the axial skeleton and sacroiliac joints, but peripheral arthritis and enthesitis 
can also occur. Characteristic symptoms of AS are spinal stiffness and loss of spinal 
mobility which originate from spinal inflammation, structural damage (syndesmophytes 
bridge between vertebrae that results in the iconic “bamboo spine”), or both. Extra-
articular manifestations of the disease also include anterior uveitis, osteoporosis, cardiac 
disease with primarily valvular involvement, renal disease, lung disease, gastrointestinal 
disease, and skin disease [30-32]. 
Diagnosis of AS is based on the modified New York diagnostic criteria, initially 
proposed in 1984 [33].  
These criteria required the evidence of advanced sacroiliitis (unilateral grade 3 or 4 
sacroilitis or bilateral grade 2 to 4 sacroilitis) on radiographic imaging together with any 
one of three clinical criteria: inflammatory back pain, limitation of the motion of the 
lumbar spine, and chest expansion. Although these criteria are quite specific, they do 
not allow an early diagnosis of the disease, for this reason recently, have been 
developed other criteria that take into account MRI images, able to highlight the early 
lesions [7].  Therefore, considering that sacroiliitis is the hallmark of AS, conventional 
radiography is sufficiently sensitive in establishing more than 95% of patients having 
structural changes in the sacroiliac joints, while the detection of typical syndesmophytes 
could be useful for diagnosis in individual patients. Furthermore, MRI could provide an 
additional diagnostic benefit in visualising the active inflammation in early stages of the 
disease. Laboratory indices, as CRP and ESR, are only a support tool in diagnosis of 
AS, in fact only half of AS patients have raised CRP concentrations. In addition the 
correlation of disease activity with laboratory indices of inflammation is restricted.  AS 
is strongly associated with HLA-B27, but as stated above HLA-B27 is not sufficient to 
diagnose the disease. However, associations with AS are firmly established for subtypes 
B*27:02 (Mediterranean populations), B*27:04 (Far Eastern populations), B*27:05 
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(white and worldwide populations), and B*27:07 (South Asian and Middle Eastern 
populations), while the subtypes B*27:06 (Southeast Asian populations) and B*27:09 
(southern Italian and Sardinian populations) are not associated with AS [34]. In addition 
to HLA-B27, definite associations have been identified with the non-MHC genes, 
IL23R (interleukin-23 receptor) and ERAP1 (endoplasmic reticulum aminopeptidase 1), 
and with the gene deserts 2p15 and 21q22. Furthermore, there is strongly suggestive 
evidence implicating other genes including IL1R2 (interleukin-1 receptor 2), ANTXR2 
(anthrax toxin receptor 2), TNFSF15 (tumor necrosis factor (ligand) superfamily, 
member 15), TNFR1 (tumor necrosis factor receptor 1) and TRADD (Tumor necrosis 
factor receptor type 1-associated death domain protein) [35]. 
Treatment goals for AS include reducing symptoms, improving and maintaining spinal 
flexibility and normal posture, reducing functional limitations, maintaining the ability to 
work, and decreasing the complications associated with the disease. 
According to recommendations for the management of AS proposed by ASAS working 
group and European League Against Rheumatism (EULAR), the best treatment of the 
disease is a combination of non-pharmacological (spa treatment, education and physical 
therapy) and pharmacological methods. The standard treatment of spinal pain and 
stiffness for patients with AS consists of NSAIDs including selective inhibitors of 
cyclo-oxygenase 2, and structured exercise programmes. Continuous NSAIDs treatment 
is recommended for persistently active, symptomatic disease, with doses adjusted in 
accordance with the severity of symptoms. DMARDs, such as methotrexate and 
sulfasalazine, have not been shown to be effective in AS and more in general in axial 
SpA. Anti-TNF therapy should be given according to ASAS recommendations in 
patients who have had inadequate response to at least two NSAIDs used for 4 weeks or 
more, or in patients who develop unacceptable side effects (cardiovascular, 
gastrointestinal, and renal effects) [36-38]. 
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1.3 Psoriatic arthritis 
Psoriatic arthritis (PsA) is a chronic inflammatory arthritis associated with psoriasis and 
characterized by: asymmetric distribution, distal interphalangeal joint involvement, 
dactylitis (inflammation of the whole digit), enthesitis, spinal involvement, and 
association with HLA-B27. On the basis of these characteristics, PsA has been 
classified as a HLA- B27-associated SpA [39]. As stated above, the prevalence of PsA 
ranges from 0.01% (95% CI: 0.00-0.17) in the Middle East to 0.19% (95% CI: 0.16-
0.32) in Europe [8], and is equal to 0.42% (95% CI 0.31–0.61) in Italy according to an 
only study conducted on subjects coming from the centre of Italy [9]. PsA affects man 
and women equally with onset typically between the ages of 30-50 years. Skin disease 
usually predates the onset of joint disease by an average of 10 years. 
PsA is a heterogeneous disorder traditionally classified into five subtypes including: 
asymmetric oligoarticular pattern, which involves five or fewer joints (usually medium-
large joints, e.g, wrist and knee); symmetric polyarticular pattern, which predilects the 
metacarpophalangeal and proximal interphalangeal joints; distal interphalangeal joint 
disease pattern; spondyloarthropathy, affecting the sacroiliac joints and the apophyseal 
joints of the spine, whose presentation is similar to AS but it can usually differentiated 
from the later age of onset and presence of psoriasis; and arthritis mutilans, which is the 
most severe form, in which extensive bone destruction and remodelling result in 
extreme deformities and loss of function [40]. Specific features of PsA are dactilitys 
(swelling of a finger or toe, also called as ‘sausage finger/toe’) and enthesitis, usually 
affecting the Achilles tendon, but the most important element is the personal or family 
history of psoriasis. In reality, patients rarely fit closely into one subtype and the pattern 
of joint involvement changes over time, therefore the pattern at presentation is not 
particularly useful for classification.  
Therefore, in 2006, the Classification for Psoriatic Arthrithis group proposed the 
CASPAR (ClASsification criteria for Psoriatic ARthritis) criteria, that include both 
clinical and radiological features, resulting in a sensitivity of 98.7% and a specificity of 
91.4%. To meet the CASPAR criteria, a patient must have inflammatory articular 
disease (joint, spine, or entheseal) accompanied by a score higher than/equal to 3 
resulting from the sum of the following 5 criteria: 1) evidence of current psoriasis, or a 
personal/family history of psoriasis; 2) typical psoriatic nail dystrophy including 
onycholysis, pitting, and hyperkeratosis observed on current physical examination; 3)  a 
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negative test result for the presence of rheumatoid factor; 4) current dactylitis; 5) 
radiographic evidence of juxtaarticular new bone formation, appearing as ill-defined 
ossification near joint margins (but excluding osteophyte formation) on plain 
radiographs of the hand or foot [41].  These criteria are also considered the standard 
inclusion criteria in clinical trials involving patients with PsA.  
Conventional radiology shows the classical features of the PsA comprising the 
combination of erosive change with bone proliferation, in a predominantly distal 
distribution (specially interphalangeal joints). In the case of enthesitis and tenosynovitis 
(e.g. dactylitis) of particular importance are the echo-power Doppler and MRI.  
Moreover, PsA also lacks of laboratory diagnostic markers. The most popular 
laboratory markers of inflammation, such as ESR and CRP, are elevated in only half of 
the patients, as demonstrated in a multicentre study conducted on a large cohort of 
Italian PsA patients [42]. Interestingly, these indices are significantly elevated in elderly 
onset PsA, probably reflecting more increased levels of proinflammatory cytokines in 
comparison with younger onset PsA and a more severe outcome [43]. Furthermore, 
elevated levels of ESR have been proposed, as one of the best predictors of damage 
progression and, while low levels of ESR seems to be protective. Moreover an ESR >15 
mm/h is one of the factors associated with an increased mortality in PsA [44].  The 
synovial fluid effusion is much higher in PsA than in other arthropathies. When 
available, synovial fluid analysis may offer additive information useful for the 
diagnosis, such as the increased number of leukocytes, which underlines the 
inflammatory nature of the effusion even in a patient with normal serum levels of acute 
phase response. Some biomarkers are utilised to differentiate PsA from other diseases 
more than to characterize PsA. For example in polyarticular PsA, which may be in some 
cases indistinguishable from rheumatoid arthritis, the rheumatoid factor or antibodies to 
cyclic citrullinated peptides (anti-CCP), may be useful to better identify rheumatoid 
arthritis. However, rheumatoid factor was found in 5- 13% of patients with PsA, and 
anti-CCP may be observed in almost similar percentage [45].  
Among the genetic markers most studied, alleles at the HLA locus on chromosome 6p 
have been most informative. HLA associations with PsA have been demonstrated 
particularly for class I alleles, at the B and C loci. Compared to most of the rheumatic 
diseases, heredity plays a particularly important role in this form of SpA. About 15% of 
the relatives of a patient with psoriasis manifest the PsA, and a further 30-45% have 
psoriasis. The most involved allele for psoriasis is HLA-CW6 and in particular, the 
	  	   15 
presence of HLA-CW*0602 is associated with more severe and early onset in both 
psoriasis and PsA. Moreover, HLA-CW*0602 alleles confer a phenotype characterized 
by a longer interval (> 10 years) between the onset of skin psoriasis and arthritis [46]. 
HLA-B16, HLA-B38 and HLA-B39 are have been associated with peripheral arthritis 
in PsA, while HLA-B27 with spondyloarthropathy subset, as in AS. In subjects B27 and 
B39 positive, musculoskeletal manifestations seems to occur simultaneously with the 
skin manifestations [47]. There is also evidence that other genes in the HLA region on 
chromosome 6 may be important in PsA, including TNF-α and its promoter. Other 
genes, as Interleukin (IL)-1 gene cluster on chromosome 2q12-13 and IL-23R gene on 
chromosome 1p31 were found to be associated with PsA [39, 48]. 
The management of PsA requires attention to both skin and joint manifestations. 
Several groups of expert have developed various sets of recommendations, either at the 
national level or at the international level. At the international level, two 
recommendations sets are available: these have been developed by the Group for 
Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and by the 
EULAR, published in 2009 and 2012 respectively [49, 50]. These recommendations 
deal mainly with pharmacological treatments, although an optimal management of 
patients with PsA should also include non- pharmacological strategies with patient 
education and regular exercise.  
Both recommendations sets propose a graduated, overlapping approach to the treatment 
of PsA, in particular propose NSAIDs drugs as first treatment for joint inflammation 
then, if necessary, introduction of conventional synthetic DMARDs (such as 
methotrexate, sulfasalazine and leflunomide), and finally, if inflammation persists, 
introduction of anti- TNFα. The main pillar of pharmacological treatment is represented 
by DMARDs [51].   
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1.4 Genetics of Spondyloarthritis  
The pathogenesis of SpA encompasses a complex array of genetic, immunological and 
environmental factors. Genetic factors have long been recognized to play an important 
role in pathogenesis of SpA. The most consistent and dominant genetic effect of AS and 
PsA is located within the major histocompatibility complex (MHC) region, but several 
genome-wide association studies (GWAS) identified a number of genes associated with 
SpA and located in non MHC regions. 
1.4.1 MHC-related genetics 
1.4.1.1 HLA-B27 genetics 
The HLA-B27 expression is closely related to the pathogenesis of SpA, and in 
particular to the susceptibility of developing the axial location. However, the prevalence 
of this factor varies depending on the subtype (80- 90% in patients with AS, 50-75% in 
patients with other SpA subtypes) and geographic area. Although the presence of HLA-
B27 in 80–90% of patients with AS suggests a direct and dominant effect of the gene 
encoding the molecule, the mechanisms underlying the striking association of SpA with 
the HLA-B27 remain poorly understood [2].  
The HLA-B27 gene consists of at least 132 different alleles coding for 105 different 
protein subtypes (named HLA-B*27:01 to HLA-B*27:106). The most common 
subtypes associated with AS are HLA- B*27:02 in Mediterranean populations, HLA-
B*27:04 in Chinese population, HLA- B*27:05 among Caucasians, and B*27:07 in 
South Asian and Middle Eastern populations.  
Two subtypes, HLA- B*27:06 (Southeast Asian populations) and B*27:09 (southern 
Italian and Sardinian populations) do not seem to be associated with the AS [34].  
The researches carried out show subtle differences (one or more amino acid 
substitutions) between proteins encoded by the alleles associated with SpA, such as 
B*27:05, and those not associated with the disease, such as, for example, the B*27:09. 
They include the structural conformation, the protein binding, the thermodynamic 
stability, the cell surface expression and are able to influence the type of link between 
the various ligands with the translated protein [52]. 
The role of HLA–B27 molecule is to bind to peptides derived from both self-antigens 
(arising from degradation of endogenous proteins) and intracellular pathogens 
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(mimicking self-proteins) and present them at the cell surface for recognition by T 
lymphocytes. Unresponsiveness to self-peptides presented by HLA–B27 molecules is 
ensured by tolerance, which is largely acquired through thymic selection of the T-cell 
repertoire. To the contrary, antigenic challenge breaks self-tolerance, leading to 
autoimmunity. Multiple theories based on either the structural or functional properties 
of HLA–B27 have been proposed over time to explain its pathogenic role in SpA [53].  
The three main accredited hypotheses include: the presentation of arthritogenic peptides 
to autoreactive T lymphocytes, the misfolding of HLA-B27 during its biosynthesis in 
the endoplasmic reticulum (ER) leading to an unfolded-protein response (UPR) and the 
formation of heavy-chain homodimers activating natural killer cells (NK).  
While the first theory supports the autoimmune mechanism, the other two hypotheses 
argue for an autoinflammatory role of HLA-B27 in triggering innate immune responses 
[2]. 
Arthritogenic peptide hypothesis  
The arthritogenic-peptide theory, formulated in 1990 [54], is the most accepted 
pathophysiological framework for SpA. It was assumed that HLA–B27 molecules 
binding to pathogenic antigens (e.g. intracellular bacteria or an ubiquitous virus) 
activates cytotoxic T lymphocytes (CTLs) response. If this antigen show molecular or 
anti- genic mimicry with a constitutive self-ligand of HLA-B27, activated CTLs 
overcome self-tolerance against that peptide, leading to autoimmunity, tissue injury and 
inflammation. There are several self-peptides revealed as possible ligands of HLA-B27 
(many derived from cartilage/bone-related proteins) that show high homology to 
peptides derived from pathogenic bacterial proteins [52].  
The arthritogenic-peptide theory has been supported by the identification, in the 
synovial fluid of AS patients, of autoreactive HLA–B27–restricted CTLs that recognize 
peptides derived from intracellular bacteria as well as uninfected healthy cells [55]. 
Other evidence for this hypothesis is provided by the triggering of SpA by 
gastrointestinal or urogenital infections, and the presence of HLA-B27-restricted CTLs 
that are reactive against bacterial antigens as well as against self-proteins from cartilage 
in the inflamed joint. The observation that the onset of disease is often preceded by 
infection with enteric bacteria has contributed to the continued popularity of this theory. 
However, there are several points leading to think that additional hypotheses could 
explain HLA-B27 association with the SpAs’ pathogenesis. First of all the arthritogenic 
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peptide has not been demonstrated [56], moreover, two indipendent groups proved that 
transgenic rats developed inflammatory phenotype independently to CD8+ T-cells [57, 
58]. Therefore two additional hypotheses have emerged to explain the role of HLA-
B27.  
Misfolding hypothesis  
The proper folding of a protein is closely related to its function. Therefore cellular 
quality control processes, generally, degrade partially folded or misfolded proteins to 
avoid the totally or partially loss of function and the activation of abnormal processes.  
Class I molecules associate in ER with β2-microglobulin (β2m) and antigenic peptides 
for cell surface expression and presentation to T-cells. However, HLA-B27 can form 
covalent homodimers and polymers though a cysteine-67 residue in the α1 domain. 
Misfolded HLA-B27 heavy chains tend to accumulate in ER, triggering ER stress, 
which leads to activation of UPR [59] resulting in activation of nuclear factor κappa-
light-chain-enhancer of activated B cells (NF-κΒ). In certain cell types, especially in 
monocytes/macrophages, the activation of NF-κΒ induces the release of pro-
inflammatory cytokines, such as TNF-α, IL-1, IL-6, favouring inflammatory processes 
[60].  This hypothesis was confirmed by the finding that misfolded HLA-B27 molecules 
and UPR activation were observed in transgenic rats with inflammatory disease [61]. 
On the contrary, the study of a transgenic rat model, in which arthritis, spondylitis, and 
enthesitis were developed even though the accumulation of HLA-B27 misfolded heavy 
chains was reversed by increasing the expression of β2m protein, challenged this theory 
[62].  
Cell surface HLA-B27 homodimers hypothesis  
HLA-B27 heavy chains can form homodimers and polymers independently in the ER 
and at the cell surface. Generally, the cellular quality control processes ensure that only 
the correctly folded MHC class I-peptide complexes are exported to the cell surface, on 
the contrary misfolded HLA-B27 molecules accumulate in ER, as previously described, 
and activate the UPR. The HLA-B27 heavy chain homodimers detected at the cell 
surface, are thought to be produced locally during endosomal recycling [63]. 
HLA-B27 homodimers produced at cell surface bind to specific receptors expressed on 
NK cells, T-lymphocytes, and myelomonotic cells playing an immunomodulatory effect 
in the pathogenesis of autoimmune disorders HLA-B27-associated [64].  
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This hypothesis was supported by the finding that the number of NK and CD4+ T-cells 
expressing a receptor which recognizes HLA-B27 homodimers but not heterodimers 
increase in HLA-B27 positive patients [65].  
Other findings challenged this hypothesis. For example, the residue Cys67, critical in 
homodimers formation, exists in HLA-B27 subtypes related to SpA as well as in 
subtypes not SpA related [53].  
HLA-B27 is the most important gene predisposing to AS, but it not seems to be the only 
one. In fact, studies in twins estimate that HLA-B27 contributes only 20–30% of the 
total heritability, whereas the whole MHC accounts for about 40–50% of the genetic 
risk. In addition, fewer than 5% of HLA-B27 carriers in the general population develop 
disease. Beside HLA-B27, other MHC genes such as HLA-B60 and HLA-DR1 seem to 
be associated with AS. These considerations suggest the contribution of additional 
genes in the pathogenesis of SpA [2]. 
 
1.4.1.2 TNFA genetics 
Moreover, non-HLA genes within the MHC region have been implicated in SpA but the 
existence of long-range linkage disequilibrium at 6p21 does not allow a stringent 
distinction to be made between true susceptibility alleles and markers that are simply 
linked to the disease. From a biologic point of view, the association between TNFA 
promoter single nucleotide polymorphisms (SNPs) and SpA is of particular interest, 
because increased levels of various cytokines (TNF, IL-1, IL-6, and IL-18), derived 
primarily from monocyte/macrophages, have been observed in the psoriatic skin, 
synovial fluid, and synovial membrane of patients with PsA [66], as well as in blood of 
AS patients. Moreover its expression by peripheral T cells correlated well with AS 
activity [67, 68]. In this context, it is assumed that the levels of TNF-α in vivo may be 
affected by polymorphisms of the TNFA gene. The study of the TNFA promoter 
polymorphisms is of particular interest not only because of their potential functional 
role in pathogenesis of SpA, but also because the most biologic drugs used to treat the 
disease targets the TNF-α protein. 
TNFA, the gene encoding TNF-α is located in the class III region of the major 
histocompatibility complex on chromosome 6 between the HLA-B and HLA-DR genes. 
Several TNFA polymorphisms have been identified inside the TNFA promoter at the 
positions (relative to the transcription start site): −1031 (T>C), −863 (C>A), −857 
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(C>T), −851 (C>T), −419 (G>C), −376 (G>A), −308 (G>A), −238 (G>A), −162 
(G>A), and −49 (G>A) (Figure 6). Some of these have also been shown to influence the 
rate of transcription and protein production of TNF-α and TNF-β associations with 
diseases [69, 70].  
 
 
 
Figure 6. Location of TNF gene within the MHC region. The arrow indicate the transcriptional 
orientation of TNF gene. The position of the SNPs within TNF gene is indicated [69]. 
 
Although the association between polymorphisms in the TNFA promoter region and 
SpA diseases has been reported in various studies and different populations, the role of 
these polymorphisms in SpA patients is still unclear.   
Controversial results emerged studying the relation between TNFA SNPs and SpA. 
TNFA polymorphisms seems to have no independent effect on AS susceptibility [71, 
72] but their modulating effect on TNF-α expression were well relevant to the 
phenotypic diversity in AS [73, 74]. In contrast, other studies demonstrated an 
association of −308G>A polymorphism with susceptibility to AS [75, 76]. Moreover, 
the A allele was thought to have a protective role against AS [71, 77], and was 
associated with: a lower risk of developing AS, with the age at disease onset, disease 
severity and response to anti-TNFα treatment [78]. Höhler and co-workers 
demonstrated an increased frequency of the TNF-308G allele among patients with PsA 
suggesting an independent predisposition to the development of arthritic complications 
[79]. Interestingly, an association of this promoter allele has been reported in German 
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[80, 81] and Scottish [82] patients with AS, although this association was not found in 
Spanish [83], and British AS cohorts [81].  
Kaijzel et al., observed a significantly decrease of TNFA-238A allele in HLA-B27 
positive AS patients. Assessment of association showed that the TNF-238G allele is in 
linkage disequilibrium with the HLA-B27 allele, suggesting that the association 
between TNFA-238G and AS is secondary to the HLA-B27 gene [84]. On the contrary, 
Höhler and co-workers observed a highly significant association among TNFA-238A 
polymorphism and psoriasis and PsA, which was independent of HLA-B27. The 
authors also demonstrated that this variant decreased transcriptional activity of the 
TNFA promoter and consequently reduced production of TNF-α by peripheral blood 
mononuclear cell [79]. Higher prevalence of both wild-type alleles at positions -238 
(GG) and -1031 (TT) were found with moderate to severe psoriasis compared to healthy 
control group [85]. 
A large genetics study, conducted on 909 PsA patients and 1315 healthy controls, 
robustly demonstrated that TNFA-857T represents a risk allele for PsA independent of 
the HLA-CW6 [86]. Although the functional role of TNFA-857T remains to be 
determined, it has been shown that allele T increases the transcription of TNF-α [87].  
In summary, the data from the studies on TNFA genetic polymorphisms seem to vary 
from one study to another. This variation could be related to the differences in the 
ethnic origin or the number of the individuals under study, other than to the low 
statistical power and clinical heterogeneity in the available studies. Although these 
polymorphisms do affect the expression level of TNF-α, the activation and abundance 
of other molecules that interact directly or indirectly with the promoter sequence must 
affect the expression of TNF-α.  
 
1.4.2 Non MHC-related genetics 
Recently, GWASs have identified several SNPs in non-MHC genes (involved in innate 
and adaptive immunity) significantly associated with SpA, such as: ERAP1, IL23R, 
IL1R2, ANTXR2, CARD9 (caspase recruitment domain family, member 9), TNFSF15, 
TNFR1 and TRADD [88, 89].  
A strong association has been identified with the combination of three polymorphisms 
(rs17482078, rs10050860 and rs30187) in the ERAP1, a gene that interacts with HLA-
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B27 and is involved in the intracellular processing of the antigen. The mechanism by 
which ERAP1 predisposes to SpA remains unknown, but one hypothesis is that ERAP1 
potentially contributes to the pathogenesis of AS, altering HLA-B27 peptide 
presentation [90].  
A GWAS, conducted by Australo-Anglo-American Spondyloarthritis Consortium 
(TASC) reported 14 SNPs in and around IL1R2 with at least nominal association with 
AS. IL-1R2 binds IL-1A and IL-1B with high affinity, and the IL-1 antagonist IL-1RA 
with lower affinity. IL-1R2 is cleaved from cell membranes, possibly by ERAP1, and 
acts as a receptor, interfering with the binding of IL-1 to IL-1R1. One possible 
explanation for the associations of ERAP1 and IL1R2 with AS is that the disease-
associated genetic variants affect cleavage of IL-1R2 from the cell surface [88].  
IL-23R is another gene strongly associated with SpA and especially with AS, PsA and 
IBD. Several studies confirmed the role of polymorphisms in that gene in predisposition 
to the development of AS and PsA, but also on disease severity [91]. Polymorphisms of 
IL-23R seem to be involved in T helper (TH) 17 lymphocyte activation/differentiation 
[89].  
Strong evidences support the association of ANTXR2 variants with AS. Two GWAS 
identified eight SNPs associated with AS, the strongest being with rs12504282. Seven 
of these SNPs were associated with HLA-B27-positive subgroup, but none was 
associated with HLA-B27-negative AS [92]. ANTXR2 encodes the protein capillary 
morphogenesis protein-2 (CMP2), a transmembrane protein expressed during capillary 
morphogenesis to bind laminin and collagen IV. It is known that recessive mutations of 
ANTXR2 cause juvenile hyaline fibromatosis and infantile systemic hyalinosis, but the 
functional mechanism in AS is still unclear [89]. 
SNPs in CARD9 and CARD14 genes, encoding member of the family of caspase 
recruitment domain-containing scaffold proteins and involving in the recruitment and 
activation of the NF-kB pathway, have been also shown in association with AS [93] and 
PsA [94], respectively.  
A strongly suggestive evidence of the association of a region on chromosome 9q31-4, 
near TNFSF15, with SpA has been reported [95]. The SNPs of TNFSF15 gene, are also 
associated with Crohn’s disease, but it is not clear whether TNFSF15 is the true disease-
associated gene in this region, either it is a candidate [96]. Following binding to another 
TNF superfamily member, DR3 (death receptor 3), TNFSF15 has been shown to 
stimulate the proliferation of TH17 lymphocytes, and in an inflammatory colitis mouse 
	  	   23 
model, to upregulate TH1 and TH17 lymphocyte activity [97].  
Two SNPs (rs9033, rs868213) of TRADD gene, have been also shown as strongly, but 
not definitly, associated with AS. In addition to being a key component of the TNFR1-
signaling cascade, TRADD is involved in signalling from the innate immunity receptors 
Toll-like receptors TLR3 and TLR4, and in DR3 signalling [98].  
 
1.4.2.1 TNFRSF1A genetics 
TNF-α, is one of the cytokines of particular interest in the propagation and perpetuation 
of inflammation in SpA. The key role of TNF has been also shown through the 
effectiveness of TNF blockers, but the mechanism driven by TNF remains unclear. 
Furthermore, remains poorly understood which form of TNF (soluble or 
transmembrane), which receptor (TNFR1 or TNFR2) and which target cells are 
predominantly involved in SpA. 
TNF-α is primarily produced as a transmembrane form (tmTNF) that can be cleaved by 
the TNF-α converting enzyme (TACE) into a soluble 51-kDa homotrimeric cytokine 
(sTNF). The two TNF-a receptors, TNFR1 and TNFR2, bind with different affinities 
the sTNF-α and the tmTNF-α: TNFR1 binds both forms equally well; TNFR2 has a 
higher affinity for the tmTNF. 
TNFR1 is constitutively expressed in most tissues and is considered the key mediator of 
TNF-α signalling, whereas TNFR2 is highly regulated and generally expressed in cells 
of the immune system. Both receptors contain four cysteine-rich domains in their 
extracellular domains and the pre-ligand assembly domain. The extracellular domain 
can be cleaved by proteases, releasing soluble receptors fragments (sTNFR1 and 
sTNFR2). The soluble receptors by binding their ligand in the circulation neutralize 
TNF-α signalling. Based on this, the anti-TNF agents are compounds that have been 
engineered as IgG dimeric fusion proteins, which mimick the soluble receptors 
fragments [99]. The differences between TNFR1 and TNFR2 intracellular domains, 
explain the different signalling events evoked by TNF-α stimulation as depicted in 
Figure 7.  
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Figure 7. TNF-TNFR signalling mechanisms are mediated via intracellular protein complexes. 
The binding of TNF-α to TNFR1 (a) and TNFR2 (b) activates different pathways [99].  
 
TNFR1 and TNFR2 are encoded by the human TNFR genes, which are located on the 
short arm of chromosome 12 (12p13) and cromosome 1 (1p36) respectively. 
Polymorphisms of the TNFR genes have been described and associated with the 
susceptibilty for development of different diseases, e.g. diabetes type 1 and sepsis [100, 
101].  
In addition to polymorphisms in TNFA promoter and in TRADD gene, several SNPs in 
TNFRSF1A (tumor necrosis factor (receptor) superfamily, member 1A) gene, the gene 
encoding TNFR1, were also found in association with AS. The TASC study, 
demonstrated that the strongest TNFRSF1A gene SNP associated with AS, was 
c.625+10A>G (rs1800693), with respect to other SNPs moderately associated [88]. 
Karaderi et al., also demonstrated the association between AS and TNFRSF1A in 
Caucasians and Chinese population [102]. Davidson et al., found a significant 
association between another TNFRSF1A gene SNP (rs4149577) and AS in Chinese 
population [103]. 
The particular interest for TNFRSF1A gene derives also from the fact that it is also 
known to be the genetic cause of the autosomal dominant autoinflammatory disorder 
TRAPS (Tumor necrosis factor Receptor-Associated Periodic Syndrome). To date, 
more than 100 different TNFRSF1A mutations have been reported among TRAPS 
patients and listed on the INFEVERS website. All the mutations related to TRAPS are 
located on extracellular domains of TNFR1, CRD1 and CRD2, rispectively involved in 
the homotrimeric formation and in the ligand binding. Mutations in the gene result in 
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different aberrant functions of the protein that involve modification in the shedding or 
in protein folding or in intracellular signalling of TNFR1. The shedding hypotesis 
suggests that defective TACE-induced shedding of cell surface TNFR1 leads to 
decreased sTNFR1 available to buffer the effect of TNF, and then increased TNFR1 
activation. Mutations can also result in a protein with structural defects that is incapable 
to reach the cell surface and it accumulates in the ER. Oligomers reteined in the ER can 
form trimers and constitutively activate, in the cytoplasm, the NF-κΒ signalling. 
Furthermore the TNFRSF1A mutations can increase mitochondrial respiration and 
reactive oxygen species production, potentiating MAPK (Mitogen-activated protein 
kinase) signalling by inhibiting MAPK phosphatases [104-111]. 
The most frequent mutations are the Arg92Gln (R92Q) and Pro46Leu (P46L) 
substitutions, which are associated with a mild TRAPS phenotype with low penetrance 
[112]. In the last years it has been compared a high frequency of R92Q variant in other 
inflammatory disorders as rheumatoid arthritis, multiple sclerosis [113- 115]. Recently 
Amigues and colleagues have presented an atypical case of AS in a patient carrier of 
R92Q. The Authors conclude that, because of arthralgias and flares of sacroiliitis, 
typical manifestations of AS, were always associated with other symptoms of TRAPS, 
the presence of R92Q mutation probably confers particularly inflammatory 
presentations to AS [116].  
 
1.4.2.2 MEFV genetics 
In the context of inflammation and in particular of autoinflammation, an interesting 
potential candidate is MEFV (Mediterranean fever) gene. This gene, located on 
chromosome 16p13.3, encodes a 781-aminoacid protein, namely pyrin or marenostrin, 
involved in the control of inflammation through regulation of leukocyte apoptosis and 
activation of IL-1β and NF-κB. Missense variations of the gene have been identified as 
causes of Familiar Mediterranean Fever (FMF), an autosomal recessive 
autoinflammatory disease [117, 118]. To date, 199 sequence variants have been 
identified in MEFV gene, mainly located in exons 2 and 10. The most common 
identified missense variations among FMF patients, also considered disease-causing 
mutations, are: M680I, M694V, M694I, and V726A in exon 10; R202Q and E148Q in 
exon 2 [119, 120]. Two different models have been proposed to explain why mutations 
of pyrin lead to the development of FMF: in the first pro-inflammatory model, the 
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mutated protein promote a process of hyper- or auto-activation of the inflammosome, 
while in the second anti -inflammatory model the mutated protein would not be able to 
inhibit the activation of caspase–1. In both models, however, the abnormal activation of 
the inflammosome is central in the initiation of the disease process. The inflammosome 
is a multiprotein complex that mediates intracellular activation of inflammatory 
caspases (caspase-1 and caspase-11). The main consequence of the activation of 
caspase-1 is the secretion of inflammatory cytokines IL- 1β, IL- 18 and IL- 33 [121]. 
Considering that muskoloskeletal involvement, mostly in the form of arthritis, is the 
second common manifestation of FMF and shows some similarity to the SpA [122, 123] 
and the AS, are very common among FMF patients and among their first-degree 
relatives in the Turkish population, the MEFV variations have been proposed as a 
contributing genetic factor to AS. It has been suspected that the upregulation of the 
inflammatory response may predisposes MEFV to certain types of inflammatory 
conditions. Furthermore febrile episodes, acute rheumatic fever and rheumatoid arthritis 
are reported to be more frequent in MEFV carriers than in controls [124]. Moreover, 
considering that FMF is mainly prevalent in Jews, Turkish, Armeninans and Arabs, and 
the carrier frequency of MEFV variations in these populations has been reported to be 
as high 39%, several association studies have been conducted in Turkish population 
[125-130]. Controversial results were found. In particular, Durmus et al., found a 
similar MEFV mutation frequency in AS patients compared to controls, though MEFV 
mutations exacerbated the severity of disease [129]. On the contrary Cinar et al, 
demonstrated a high frequency of MEFV mutations (M694V, M680I, V726A, F479L, 
M694I, P369S) among AS patients, but no significant differences were found between 
MEFV carriers and non-carriers with respect to clinical and demographic 
characteristics, as well as in NSAIDs response rate [130]. Anyhow, higher frequency 
was observed for M694V mutation in the AS patients than in controls [124, 127, 130]. It 
has been concluded that MEFV gene variations can be considered a potential 
geographic-specific pathogenetic factor [124]. 
Genetic studies strongly suggested the presence of non-MHC genes involved in SpA. 
While GWASs have yielded great insights into the genes that contribute to the 
pathogenesis of SpA, replication in large cohorts, fine mapping, together with 
functional studies of genetic variants identified, are warranted to better understand 
susceptibility, pathogenesis, and to develop more effective therapy.  
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1.5 Response to TNF-α inhibitors and genetics  
The inflammatory nature and the relevant role of TNF-α in the pathogenesis of SpA 
pose the basis of treatment with drugs targeting the TNF-α pathway.  
TNF-α inhibitors comprise two main types of agents: monoclonal antibodies (mAbs) 
(infliximab, adalimumab, golimumab and certolizumab) and soluble receptors 
(etanercept). Infliximab is a chimeric mouse-human anti-TNFα mAb composed of a 
murine variable region (25%) and a human IgG1 constant region (75%). Adalimumab 
and golimumab are fully humanized anti-TNFα mAbs, which are indistinguishable from 
the normal human IgG1. Infliximab, adalimumab and golimumab differ in their IgG1 
isotypes, the Fc regions of which govern effector functions: complement fixation and Fc 
receptor-mediated biological activities. Certolizumab is a Fab’fragment portion of 
humanized anti-TNFα mAbs lacking of the Fc portion, therefore lacking of effector 
funtions. Its hinge region is linked to two cross-linked chains of polyethylene glycol 
(PEG) to enhance solubility and hal-life in vivo. Etanercept is a genetically engineered 
fusion protein composed of a dimer of the extracellular portions of human TNFR2 
linked to the Fc portion (CH2 and CH3 domains) of human IgG1 [131,132]. The 
structures of TNF-α inhibitors are schematically represented in Figure 8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. TNF-α	  inhibitors: the molecular structures [131]. 
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TNF-α	   inhibitors, other than molecular structures, differ also for their binding 
specificities and the manner in which they neutralize TNF-α. Their mechanism of action 
is then quite different. Infliximab binds to both monomer and trimer forms of sTNF, 
whereas etanercept bind only to the trimer form, suggesting that they probably bind to 
different epitopes on sTNF (Figure 9A). As bivalent mAbs, infliximab and adalimumab 
are capable of binding to two TNF-α simultaneously and up to three infliximab 
molecules can bind to each TNF-α homotrimer blocking all receptor-binding sites on 
TNF-α. In this way stable complexes mAbs-sTNF are generated. In contrast, etanercept 
is supposed to form 1:1 complex with the TNF-α trimer in which two of three receptor-
binding sites on TNF are occupied by etanercept, and the third receptor-binding sites is 
open, resulting in relatively unstable complexes (Figure 9B). In addition, TNFR2 is 
known to have fast rates of association and dissociation to TNF-α, suggesting that 
etanercept may only transiently neutralizes the activity of TNF-α molecules [131, 133].  
Infliximab, adalimumab, etanercept and certolizumab bind also to tmTNF with similar 
affinities that are lower than for sTNF. As in the case of sTNF, up to three molecules of 
infliximab can bind one tmTNF, one etanercept can bind one molecule of tmTNF [132]. 
 
 
 
 
 
 
 
 
 
 
 
Figure 9 A-B. Infliximab versus etanercept: schematic illustration summarizing differences in 
binding specificities [133]. 
 
Although the binding and neutralizing activities against TNF-α are common 
mechanisms of action of these drugs, pharmacokinetic effects may influence the 
	  	   29 
functions of TNF-α inhibitors. Infliximab, for example, may reach higher 
concentrations in circulation following intravenous infusion and in tissue 
microenvironments than etanercept or adalimumab and, therefore, have a grater 
opportunity to bind to tmTNF on cells and induce signalling or Fc receptor-mediated 
biological activities. The elimination half- lives for infliximab and etanercept are 210 
hours and 115 hours, respectively. These differences may account for the somewhat 
different clinical efficacy of these compounds [131]. 
The efficacy and safety of these drugs has been supported by clinical trials. Placebo-
controlled randomized trials revealed similar efficacy of TNF-α inhibitors in controlling 
active disease, however, not all patients (20-40%) respond to these therapies and, 
furthermore they are not exempt from serious adverse events.  
TNF-α inhibitors have been associated with increased risk of infections, including 
reactivation of tuberculosis and sepis, probably as result of interference with innate 
immunity, but they have not been found to be broadly immunosuppressive. Less clear 
are the effects of anti-TNFα agents on host defence against malignancies, particularly 
lymphomas. Other adverse events associated with TNF-α inhibitors were: haematologic 
disorders such as anemia and pancytopenia, demyelinating disorders and neuropathy, 
worsening of congestive heart failure, occurrence of autoantibodies and autoimmunity, 
and hypersensitivity reactions [134]. 
In the past few years new therapies have been approved for the treatment of SpA, 
increasing the therapeutic options for these patients. How best to use these drugs remain 
unclear. The development of predictors of response might identify responders and thus 
help with making therapeutic decision in clinical practice. Recently, Maneiro and 
colleagues performed a systematic review and meta-analysis of clinical trials and 
observational study to identify predictors of response to TNF-α inhibitors in patients 
affected by AS and PsA.  Male gender, HLA-B27, younger age, higher CRP level, 
higher BASDAI and lower BASFI at baseline predict better response to TNF-α 
inhibitors in AS but not in PsA [135]. 
TNF-α genetics has been hypothesized as one of the determinants causing failure of 
response in terms of both efficacy and toxicity. The majority of studies in this field were 
performed in patients with rheumatoid arthritis, while only few studies have analysed 
the role of genetic markers in the response to anti- TNFα agents in SpA patients, 
considering mainly AS [136- 138]. Studies in this field, summarized in two recent meta-
analyses [139, 140], demonstrated that a better response to TNF-α antagonists occurs 
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among Caucasian patients carrying the common TNFA-308G, -238G and -857C alleles 
[139]. These genetic variants, however, did not uniformly predict response to treatment, 
their effect being dependent on the type of drug and on the SpA subtype.    
In particular, G alleles of TNFA-308 and -238 could predict the response to etanercept 
(OR = 4.02 [2.24-7.23]; 5.17 [2.29-11.67]) but not to infliximab/adalimumab (OR = 
1.68 [1.02-2.78]; 1.28 [0.57-2.86]). Moreover the TNFA-308 (G>A) polymorphism 
could predict the response to TNF blockers in PsA and IBD- SpA patients, but not in 
AS patients [140].  
The relation of TNFRSF1A mutations and response to infliximab was investigated in 
patients affected by inflammatory bowel disorders. Pierik et al., demonstrated that the 
TNFRSF1A 36G mutation was associated with lower response to infliximab [141]. 
Other Authors observed a significant association between TNFRSF1A, rs767455 and 
the efficacy of infliximab in eighty Crohn’s disease patients. In particular the minor 
allele carrier of rs767455 showed a significant association with a lack of efficacy 
compared to major genotype [142]. 
Schiotis et al., investigated also the role of SNPs, located in other genes and reported as 
associated with pathogenesis of SpA, in the response to anti-TNFα agents. 384 SNPs, 
distributed in 190 genes, were tested in 121 AS patients. Among these, five indipendent 
predictors of nonresponse to the anti-TNFα therapy were identified: rs917997 in the 
IL18RAP (interleukin 18 receptor accessory protein) gene (OR 3.35, 95 % CI 1.38– 
8.15), rs755622 (OR 3.14, 95 % CI 1.19–8.22) in the MIF (macrophage migration 
inhibitory factor) gene, rs1800896 in the IL10 gene (OR 3.09, 95 % CI 1.04–9.15), 
rs3740691 (OR 2.90, 95 % CI 1.12–7.51) in the ARFGAP2 (ADP-ribosylation factor 
GTPase-activating protein 2) gene, rs1061622 (OR: 2.46, 95 % CI 1.00–6.04) in the 
TNFRSF1B (tumor necrosis factor receptor superfamily, member 1B) gene [143].  
Overall, these data further support the relevant role of inflammatory cytokines genetics 
and of the TNF pathway not only in disease pathogenesis, but also in response to 
treatment with anti-TNF-a agents. 
Pharmacogenomic studies focusing on genes involved in SpA etiology and 
pathogenesis, in order to analyse the role of allelic polymorphisms in the individual 
difference in treatment response to TNF-α inhibitors, are limited in SpA. Taking 
account the cost and the potential severe side effects of these agents, identification of 
genetic biomarkers of treatment inefficacy would be of major use for prospectively 
selecting patients that will most likely respond to such treatment.  
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2. AIMS 
 
The main aim of this retrospective study was to verify whether biochemical markers 
commonly used in clinical practice and genetic variants of HLA locus, TNF-TNFR 
pathway and MEFV play a part in increasing the risk of SpA (AS or PsA), and/or in 
predicting anti-TNFα treatment failure in subjects from the Veneto Region (North-East 
of Italy). 
Specific aims were to investigate whether diagnosis of SpA (AS or PsA) and failure of 
response to anti-TNFα drugs are associated with the followings biochemical and genetic 
markers: 
- Specific haematological and biochemical pattern of inflammation considering 
ESR and complete blood count, CRP, prealbumin, ALT, glucose, creatinine and 
uric acid;   
- HLA-B27 and HLA-CW6 haplotypes; 
- Five SNPs (−1031 T>C, −857 C>T, −376 G>A, −308 G>A, −238 G>A), in the 
promoter region of TNFA, evaluated singely or as haplotypes;  
- known or unknown variants of TNFRSF1A by the analysis of exons 2,3,4 and 6; 
- known or unknown variants of the autoinflammatory gene MEFV, by the 
analysis of exons 2,3,5 and 10. 
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3. MATERIALS AND METHODS 	  
3.1 Studied population 
A cohort of 314 subjects belonging to the Veneto Region, a North-East Italian region, 
was enrolled in this study from January to December 2014.  
The cohort comprised 223 controls (146 males and 77 females; mean age ± standard 
deviation: 46.1 years ± 10.5) and 91 patients (57 males and 34 females; mean age ±  
standard deviation: 52.2 ± 12.5 years) affected by SpA and attending the Rheumatology 
Unit of the Department of Medicine- University-Hospital of Padova (Italy). 
Among patients, 36 (39.6%) had a definite diagnosis of AS, according to the modified 
New York criteria [33] and 55 (60.4%) had a diagnosis of PsA according to the 
CASPAR criteria [41]. The mean disease duration was 15 ± 11.7 years (range 2–56 
years).  
At enrollment, 58 patients (63.7%) were under therapy with anti- TNFα agents (25 with 
Infliximab, 21 with Adalimumab, 11 with Etanercept and 1 with Golimumab), of which 
11 (19%) experienced in their clinical history, at least one switch of TNF-α inhibitor 
before entering the study. Patients were followed for at least 12 months after the 
beginning the anti-TNFα agent. At least 10 months of treatment were considered to 
define a delayed response to TNF-α inhibitors. 
The study protocol was approved by the Local Research Ethics Committee of the 
University-Hospital of Padova (Comitato Etico per la Sperimentazione, protocol 
number: 3024P/13) and all subjects gave their fully informed written consent before 
entering the study. 
  
3.2 Clinical Assessment 
All subjects attending the study were questioned about demographic (gender, age, place 
of birth, weight, height) and physiological (smoking, alcohol use) data. 
Medical (age at diagnosis, laboratory tests at diagnosis, disease duration, 
axial/peripheral involvement, enthesitis, inflammatory back pain, articular and extra-
articular manifestations, pre-existing/current drug therapy) and familiarly history 
(arthritis, psoriasis, other rheumatic diseases) data were also collected in patients. 
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Outcome Assessment 
All patients underwent clinical, clinimetric and functional examinations.  
The peripheral joint commitment was assessed through the count of tender/swollen 
joints and the evaluation of dactylitis and enthesitis indices, as the Disease Activity 
Score (DAS) [18].  
The axial involvement was investigated through the BASMI [23]. A BASMI score from 
0 to 10 indicates a condition that ranges from normal spine mobility to the severely 
restricted spinal mobility. 
To evaluate the functional statement was asked patients to fill out two validated 
questionnaires: BASFI [21] and HAQ [22]. In particular, BASFI includes 10 questions 
presented in the form of numerical scale, which explores the degree of difficulty 
encountered in carrying out specific activities of daily life and whose total score is 
calculated as an average of 10 score questions. HAQ comprises 20 questions about daily 
living activities divided into 8 categories, the sum of the scores ranging between 0-24 
and divided by 8 provides the final score on a scale 0 to 3. The highest values reflect the 
maximum impairment. 
The disease activity was evaluated by using BASDAI [13, 14] and ASDAS [15, 16]. 
BASDAI includes six questions useful to investigate the intensity of pain in the neck, 
back, hips and peripheral joints, the pain caused by contact / pressure, as well as the 
intensity and the duration of morning stiffness. ASDAS is a composite index 
comprising both, subjective measures and laboratory parameters (spine and peripheral 
joint pain, morning stiffness duration, disease activity). Values are expressed, for both,  
on a scale ranging from 0 to 10, where a score >4 identifies active disease. 
 
3.3 Haematological and biochemical indices 
For each enrolled subject, four blood samples were collected: two EDTA-K2 tubes (3 ml 
blood each), one of them for the determination of ESR and the complete blood count, 
the other one for genetic analyses; one lithium-heparin tube (3 ml blood) for the 
determination in plasma of glucose, uric acid, creatinine and alanine transaminase 
(ALT); one whole blood sample (4 ml) for the determination in serum of CRP and 
prealbumin. 
ESR was performed within 4 hours of collection on a Sysmex XE-2100 analyser (Dasit, 
Milan, Italy), which adopts a method based on light scatter, impedance, and 
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fluorescence. TEST1 analyser (Alifax, SIRE Analytical System, Udine, Italy), based on 
capillary photometry-kinetic technology, was used to perform complete blood count.  
Glucose, uric acid, creatinine and ALT levels were determined on Cobas 8000 modular 
analyser (Roche Diagnostics, USA) through the enzymatic- colorimetric assays widely 
used in routine testing and in particular: glucose: hexokinase method; creatinine: the 
Jaffé method; uric acid: uricase-peroxidase method; ALT: pyridoxal- 5-phosphate 
method, according to procedure released by International Federation of Clinical 
Chemistry and Laboratory Medicine (IFCC).  
CRP and prealbumin were determined by immunometric assays on Dimension Vista 
1500 System (Siemens Healthcare Diagnostics Inc., Deerfield, IL, USA). 
 
3.4 Genetics analyses  
Genomic DNA, was extracted from 200 µl EDTA-K2 peripheral blood using the 
MagNA Pure96 System (Roche S.p.A., Monza, Italy) according to manufacturer 
instructions. The extraction method is based on the binding affinity of the DNA to the 
glass (silica) surface of Magnetic Glass Particles. DNA was eluted in 100 µl of elution 
provided buffer. DNA concentration and purity were assessed for each sample by 
spectrophotometric measurement of the absorbance at the wavelenght of 260 nm and 
280 nm (Nanodrop spectrophotometer, Thermo Fisher Scientific, Wilmington, DE, 
USA). DNA concentration was 72.7 ± 17.8 ng/µl (mean ± standard deviation) with a 
purity, calculated as 260/280 nm ratio, of 1.86 ± 0.13 (mean ± standard deviation).  
 
3.4.1 HLA-B27 and HLA-CW6 haplotypes detection 
HLA-B27 and HLA-CW6 alleles presence was determined by two molecular genetic 
testing using commercially available CE-IVD microarray: EUROArray HLA-B27–
Direct and EUROArray HLA-CW6–Direct, respectively (Euroimmun AG, Luebeck, 
Germany).  
EUROArray technology is capable to detect all together, 130 different HLA-B27 
subtypes (B*27:01–B*27:105) or 51 HLA-CW6 subtypes (C*06:02:01:01–C*06:55), 
which differ only in some bases. 200 ng of genomic DNA, previously isolated from the 
enrolled subjects (patients and controls), is mixed with the ready for use polymerase 
chain reaction (PCR) reagents (DNA polymerase and validated specific primers) 
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supplied by the EUROArray kits. 
In the first reaction step, HLA gene fragments (two sequences of the HLA-B or one of 
HLA-C gene) and a b-globin gene fragment as positive control were amplified from the 
genomic DNA sample using a PCR protocol, according to the manufacturer 
instructions. The HLA-B gene sections are only amplified if the sample contains an 
HLA- B27 allele, while the HLA-C gene fragment only when the sample contains 
HLA-C06. All PCR products were labelled with a fluorescence dye during PCR 
reaction, so that they could be analysed in the second reaction step. The hybridisation of 
the fluorescing PCR product to the corresponding microarray (containing immobilised 
probes complementary to the amplified DNA) was detected using the EUROIMMUN 
Microarray Scanner. A fluorescence signal on the HLA (HLA-B27 or HLA-C06)-
specific spots indicates the presence of an HLA-allele in the analysed DNA. The 
EUROArrayScan software automatically evaluated all spot signals and, on the basis of 
these data, gave out a test result. 
 
3.4.2 TNFA gene analysis  
The genotype discrimination of five TNFA SNPs (-1031T>C, rs1799964; -857C>T, 
rs1799724; -376G>A, rs1800750; -308G>A, rs1800629; -238G>A, rs361525) was 
performed by a TaqMan dual probes allelic discrimination assay. Amplification was 
carried out with an ABI Prism 7900 HT (Applied Biosystem, CA, USA). 
50 ng of genomic DNA were amplified in a reaction mix containing primers and probes 
at a final concentration specified in Table 2 and 1X TaqMan Universal Master Mix 
(Applied Biosystem, CA, USA), in a final volume of 20 µl.   
Primers and probes sequences and thermocycling conditions were shown in Table 2. 
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Table 2. Primers, probes sequences and amplification profiles designed for five TNFA SNPs 
genotype discrimination. 
TNFA 
SNPs 
Primers,  
[Final concentration, nM] 
Probes,  
[Final concentration, nM] 
Thermocycling 
Conditions 
-1031T>C 
rs1799964 
F:5’-AGGTGAGGCCGCCAGACT-3’,  
[900] 
R:5’-TCCTCAGAGCCGCTACATGTG-3’,  
[900] 
FAM:AGCTGAGAAGACGAAG (C), 
[200] 
 VIC:AGCTGAGAAGATGAAG (T), 
[150] 
50 °C 2 min,   
95 °C 10 min,   
40 cycles 95°C 15s,  
62 °C 1 min 
-857C>T 
rs1799724 
F:5’-GGTCCTGGAGGCTCTTTCACT-3’,  
[50] 
R:5’-AGAATGTCCAGGGCTATGAAAGTC-
3’, [900] 
FAM:CCCTGTCTTCGTTAAG (C), 
[200] 
VIC:CCCTGTCTTCATTAAG (T),  
[100] 
50 °C 2 min,  
95 °C 10 min,   
40 cycles 95°C 15s,  
60 °C 1 min 
-376G>A 
rs1800750 
F:5’-CCCCTCCCAGTTCTAGTTCTATCTT-3’, 
[300] 
R:5’-CCTATTGCCTCCATTTCTTTTGG-3’, 
[900] 
FAM:CTGTCTGGAAATTAGAAG(A), 
[100]  
VIC:CTGTCTGGAAG TTAGAAG (G), 
[150] 
50 °C 2 min,  
95 °C 10 min,   
40 cycles 95 °C15s,  
60 °C 1 min 
-308G>A 
rs1800629 
F:5’-CAAAAGAAATGGAGGCAATAGGTT-
3’, [900] 
R:5’-GGCCACTGACTGATTTGTGTGT-3’,  
[900] 
FAM:AACCCCGTCCTCATG (A), 
[200] 
VIC:AACCCCGTCCCCATG (G), 
[150] 
50 °C 2 min,  
95 °C 10 min,   
40 cycles 95 °C15s,  
56 °C 1 min 
-238G>A 
rs361525 
F:5’-AAATCAGTCAGTGGCCCAGAA-3’,  
[300] 
R:5’-GCATCAAGGATACCCCTCACA-3’,  
[900] 
FAM:CTCGGAATCAGAGCAG (A), 
[200]  
VIC:CTCGGAATCG GAGCAG (G), 
[200]  
50 °C 2 min,  
95 °C 10 min,   
40 cycles 95 °C15s,  
60 °C 1 min 
TNFA: Tumor necrosis factor α, F: forward primer, R: reverse primer. 
 
 
3.4.3 TNFRSF1A gene analysis  
Exons 2, 3, 4 and 6 of the TNFΑRSF1A gene were analysed by means of denaturing 
high-performance liquid chromatography (DHPLC; Wave® 2100 Fragment Analysis, 
Transgenomic, Omaha, NE, USA) and gene sequencing (ABI PRISM 3130 Genetic 
Analyzer, Applied Biosystem, CA, USA) of identified heteroduplexes.  
Exons 2, 3, 4 and 6 of TNFRSF1Α gene were at first amplified by PCR using 100 ng of 
genomic DNA, 480 nM for each primer (forward and reverse primer), 200 µM of 
dNTPs, 1.5 mM of MgCl2, 2.5 U of Taq polymerase (AmpliTaq Gold, Applied 
Biosystems, CA, USA) and 1X manufacturer-provided buffer (Applied Biosystems, 
USA) in a final volume of 50 µl.	  PCRs were run with an initial denaturation at 95 °C for 
7 minutes, followed by 35 cycles at 94 °C for 30 seconds, 55 °C for 45 seconds and 72 
°C for 45 seconds, with a final extension at 72 °C for 20 minutes. Water was used as 
negative control in each PCR run. After amplification of DNA, to verify the presence of 
amplification products and to exclude the presence of contamination in mixes, gel 
electrophoresis of 10 µl of the amplification products was performed using 2% agarose 
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gels (E-Gel, Invitrogen, Life Technologies, Monza, Italy) with ethidium bromide as 
staining.   
DHPLC analysis was then performed using the Wave® 2100 Fragment Analysis 
(Transgenomic, Omaha, NE, USA). DHPLC is based on a reversed phase 
chromatography in which the hydrophobic stationary phase was 2 µm of alkylated 
nonporous poly (styrene- divinylbenzene) particles packed into a 4.6x50 mm separation 
column (Transgenomic). The polar mobile phase is acetonitrile. Triethylammonium 
acetate (TEAA) 0.1 M buffer (pH 7.0) is used as an ion-pairing reagent.  
This first step is the denaturation of the PCR amplicons at 95 °C for 10 minutes and a 
slow renaturation to create hetero- and homoduplexes molecules. The presence of a 
mutation can be established by the differential retention of hetero- and homoduplex 
DNA on the stationary phase under partial thermal denaturation condition. 
Heteroduplex molecules are primarily eluted from the column in an increasing gradient 
of acetonitrile (0.5% for minute). 
Homozygous polymorphism was identified in the same way by premixing 1:1 each 
amplicon with one obtained from a wild type subject to mimic a heteroduplex after the 
denaturation and renaturation step. Navigator 3.1.0 software was used to predict the 
melting temperature of each PCR fragment and the appropriate linear acetonitrile 
gradient necessary to distinguish hetero- and homoduplexes. Primers for PCR 
amplifications, amplicon lengths, DHPLC temperature and gradient conditions are listed 
in Table 3. 
 
Table 3. Primer sequences designed for the amplification of exons 2, 3, 4 and 6 of the 
TNFRSF1Α gene, and denaturing high-performance liquid chromatography (DHPLC) 
temperature conditions. 
Exon Forward and reverse primer 
sequences 
Amplicon 
bp 
Denaturing HPLC 
temperature, °C 
Timeshift Acetonitrile 
gradient % 
(Start-end) 
2 
F-5’-TCCCTCTTTGATGGTGTCTCC-3’ 
R-5’-CAGACCTGAGGGCATTCACC-3’ 
234 59.3/59.8 0/0 13.1-15.3 
3 
F-5’-TTCCTTGTGTTCTCACCCGCAG-3’ 
R-5’-TCAAGACCCGCCTGACTCTC-3’ 
214 62.7/63.2 0/0 12.9-15.1 
4 
F-5’-AGGATGCAGGACTCATACCC-3’ 
R-5’-AAAGGAAGTGCCACCGCATGG-3’ 
268 63.5 1 12.9-15.1 
6 
F-5’-GTGTTCCTCCAATGGTAGGG-3’ 
R-5’-AAGCAGGTGTTGGTCAGAGG-3’ 
258 60.5/61 0/0 13.3-15.5 
F: forward primer, R: reverse primer, bp: base pair, HPLC: high-performance liquid chromatography. 
Exons with altered elution profiles in DHPLC assay were directly sequenced. 
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TNFRSF1A gene sequencing was performed on the automatic sequencer 3130ABI 
PRISM Genetic Analyzer (Applied Biosystem, CA, USA), using 1 µL of previously 
purified (ExoSAP, GE Healthcare, Fairfield, CT, USA) amplification product mixed 
with 300 nM of each forward and reverse PCR primer, 4 µl of Big Dye terminator Mix 
(Applied Biosystem, CA, USA) in a final volume of 20 µL. Chromatograms were 
analysed with Chromas Lite 2.6.1 software (Technelysium Pty Ltd., South Brisbane, 
QLD, Australia).  
 
3.4.4 MEFV gene analysis  
The analysis of polymorphisms of the MEFV gene was performed by direct sequencing 
of exons 2, 3, 5 and 10.  
Exons were amplified by PCR (2720 Thermal Cycler, Applied Biosystem, CA, USA), 
using primers sequences shown in Table 4. 
 
Table 4. Primer sequences for the amplification of exons 2, 3, 5 and 10 of the MEFV gene.  
Exon Forward and reverse primer sequences Amplicon (bp) 
2 
F-5’-GGGGA TTCTCTCTCCTCTGC-3’ 
R-5’-CTCAAAGTCTTGGCCTCCAG-3’ 
903 
3 
F-5’-AACTTGGGTTTGCCATTCAG-3’ 
R-5’-AAGTGCCTGGCAGAGAAGAG-3’ 
438 
5 
F-5’-CCACCTCTTATCCACCTCCA-3’ 
R-5’-CTAGGCCTTAGGGGCTTCAC-3’ 
449 
10 
F-5’-CAGGTGGGGAGAACCCTGTAG-3’ 
R-5’-CCGTGGGCACAGTAACTATT-3’ 
757 
F: forward primer, R: reverse primer, bp: base pair. 
For each exon, 100 ng of genomic DNA were amplified in a reaction mix composed by 
500 nM of each forward and reverse primer, 200 µM of each deoxynucleotide 
triphosphates (dNTPs), 2.5 mM of MgCl2, 1 Unit (U) of Taq polymerase (Super Taq, 
AB Analitica, Padova, Italy), 1X manufacturer-provided buffer, 10% dimethyl sulfoxide 
(DMSO) (only for exon 2) in a final volume of 25 µl. Therefore, four different reactions 
mix was prepared for a single enrolled subject. PCR reactions were run with an initial 
denaturation at 94 °C for 5 minutes, followed by a touchdown step (94 °C for 30 
seconds, 68°C in the first cycle for 30 seconds and -0.5 °C/cycle for 9 cycles, 72°C for 
45 seconds) and more 26 cycles at 94 °C for 30 seconds, 62 °C for 30 seconds, 72 °C 
for 45 seconds, with a final extension at 72 °C for 7 minutes. Water was used as 
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negative control in each PCR run. After amplification of DNA, to verify the presence of 
amplification products and to exclude the presence of contamination in mixes, gel 
electrophoresis of 10 µl of the amplification products was performed using 2% agarose 
gels (E-Gel, Invitrogen, Life Technologies, Monza, Italy) with ethidium bromide as 
staining.  
MEFV gene sequencing was performed on the automatic sequencer 3130ABI PRISM 
Genetic Analyzer (Applied Biosystem, CA, USA), using 1 µL of previously purified 
(ExoSAP, GE Healthcare, Fairfield, CT, USA) amplification product mixed with 300 
nM of each forward and reverse PCR primer, 4 µl of Big Dye terminator Mix (Applied 
Biosystem, CA, USA) and 5% DMSO (only for exon 2) in a final volume of 20 µL. 
Two additional internal primers were also used to perform the sequence of the exon 2 
(Fint: 5’-CCCTGAGCAAACGCAGAG-3’ and Rint: 5’- 
GTACACTTCGAAGGGCCTGC-3’). Chromatograms were analysed with Chromas 
Lite 2.6.1 software (Technelysium Pty Ltd., South Brisbane, QLD, Australia).  
 
MEFV gene: R202Q SNP genotyping 
The genotype discrimination of the R202Q SNP (rs224222) in MEFV gene (exon 2) 
was performed by a TaqMan dual probes allelic discrimination assay. Probes and 
primers mix was purchased as manufacturer-provided assay from Applied Biosystem 
(Taqman SNP genotyping, catalog number C_2394721_10). 50 ng of genomic DNA 
was amplified in a reaction mix containing 1X of primers and probes mix and 1X 
TaqMan Universal Master Mix (Applied Biosystem, CA, USA) in a final volume of 20 
µl.  Amplification was carried out with an ABI Prism 7900 HT (Applied Biosystem, 
CA, USA) with a step at 50 °C for 2 minutes and 95 °C for 10 minutes, followed by a 
40 cycles at 95 °C for 15 seconds and 60 °C for 1 minute. 
 
3.5 Statistical analysis  
Mean, standard deviation (SD) or median and interquartile range (IQR) were used as 
descriptive statistics for continuous data, while χ2 and Fisher’s exact tests were used for 
categorical data. The χ2 test, Fisher’s exact test, binary logistic regression analysis, 
Student’s t test for unpaired data, analysis of variance (ANOVA) and Bonferroni’s 
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adjustement of p value for multiple testing were performed using Stata software, 
version 13.1 (StataCorp, Lakeway Drive, TX, USA). 
Hardy-Weinberg calculation 
Genotype frequencies were tested for Hardy-Weinberg equilibrium proportions using χ2 
test. For each SNP, the allele frequencies were first calculated on the basis of the 
observed genotypes. The expected genotypes frequencies were then calculated on the 
basis of the following formula:  
p2 + 2pq + q2= 1 
p and q being the observed alleles frequencies.  
 
 
Haplotype Estimation 
Haplotypes phases and frequencies were estimated by the retrospective profile-
likelihood approach using the Stata haplologit package. Odds ratio (OR) was calculated 
by logistic regression analysis using the additive model [144].  
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4. RESULTS 	  
4.1 Studied population 
In this study, a total of 314 subjects from the Veneto Region (a North-east Italian 
region) were enrolled. These included 223 controls and a cohort of 91 patients with an 
established SpA diagnosis comprising 36 AS and 55 PsA. In statistical analyses, 
patients were evaluated as a single group (SpA) in comparison to controls, or else AS 
and PsA groups were considered singly. Table 5 reports the demographic characteristics 
of controls and patients with results from the statistical analyses. The percentage of 
females was higher among PsA (49%) than AS (19%) or controls (35%), and mean age 
was lower among controls than in SpA patients (Table 5). Weight, Height and body 
mass index (BMI) did not differ between the studied groups. Gender and age were 
therefore considered as potential confounding factor in all subsequent statistical 
analyses.  
 
Table 5. Demographic characteristics in three groups: controls, AS and PsA patients. 
 
Bonferroni’s test for pairwise comparisons: *=p<0.05 with respect to controls; ***=p<0.0001 with 
respect to controls. Significant p values are reported in bold. AS: ankylosing spondylitis, PsA: psoriatic 
arthritis, M: male, F: female, SD: standard deviation, BMI: Body Mass Index.  
 
 
4.2 Clinical characteristics of SpA patients 
The clinical characteristics of the two groups of patients are shown in Table 6. Family 
history of SpA, age at diagnosis and clinical symptoms were evaluated. Back pain and 
enthesitis were more frequent among AS, while peripheral arthritis, dactylitis and 
psoriasis were more frequent among PsA patients as expected. Extra-articular clinical 
manifestations, such as uveitis, IBD or urethritis/cervicitis were rare in both groups of 
patients.  
 Controls 
(n=223) 
AS  
(n=36) 
PsA  
(n=55) 
Statistics 
Gender (M/F) 146/77 29/7* 28/27* χ2 = 8.59, p = 0.014 
Age mean±SD (years) 46 ± 11 52±13* 53±12*** F = 10.22, p=0.0001 
Weight mean±SD (Kg)  76.52 ± 15.33 76.17 ± 9.85 77.54 ± 14.24 F = 0.13, p = 0.8782 
Height mean±SD (cm)  172.77 ± 10.94 175.11 ± 6.21 170.80 ± 8.75 F = 2.01, p = 0.1354 
BMI mean±SD (Kg/m2)  25.91 ± 8.27 24.81 ± 2.73 26.50 ± 4.13 F = 0.62, p = 0.5410 
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Table 6. Clinical characteristics in AS and PsA patients at diagnosis. 
 AS (n=36) PsA (n=55) Statistics 
Family history of SpA, n (%) 10 (27.78) 45 (81.82) χ2 = 26.57, p < 0.0001 
Age at diagnosis, mean ± SD (years)  40.53 ±12.43 40.58 ±13.16 t = 0.000,  p = 0.984 
Inflammatory back pain, n (%) 35 (100.00) 36 (65.45) χ2 = 15.33, p < 0.0001 
Peripheral arthritis, n (%) 4 (11.11) 50 (90.91) χ2 = 57.42, p < 0.0001 
Enthesitis, n (%) 34 (94.44) 35 (63.64) χ2 = 11.27, p < 0.001 
Buttock pain, n (%) 33 (91.67) 15 (27.27) χ2 = 36.20, p < 0.0001 
Dactylitis, n (%) 0 (0.00) 33 (60.00) χ2 = 33.89, p < 0.0001 
Uveitis, n (%) 2 (5.56) 1 (1.82) χ2 = 0.95,   p = 0.329 
Psoriasis, n (%) 1 (2.78) 45 (81.82) χ2 = 54.38, p < 0.0001 
IBD, n (%) 2 (5.56) 2 (3.64) χ2 = 0.19,   p = 0.662 
Urethritis/Cervicitis/Diarrhoea, n (%)  4 (11.11) 14 (25.45) χ2 = 2.82,   p = 0.093 
Significant p values are reported in bold face. SpA: spondyloarthritis PsA: psoriatic arthritis, AS: 
ankylosing spondylitis, SD: standard deviation, IBD: Inflammatory Bowel Diseases. 
 
 
Outcome measures at diagnosis were also evaluated and reported in Table 7.  Only the 
BASMI index significantly differed between groups, being higher among AS than PsA.    
 
 
Table 7. Laboratory indices and outcome measures in AS and PsA patients at diagnosis. 
 AS (n=36) PsA (n=55) Statistics 
ESR, mean ± SD (mm/hr) 22.97 ± 13.91 28.62 ± 15.07  t = 3.24,   p =0.0751 
CRP, mean ± SD (mg/L) 5.85 ± 5.81 8.022 ± 6.52  t = 2.63,   p =0.1082 
DAS, mean ± SD 3.50 ± 1.33  3.49 ± 0.81  t = 0.00,   p =0.9677 
BASMI, mean ± SD  3.67 ± 1.29 2.53 ± 1.33  t = 16.36, p <0.0001 
BASFI, mean ± SD 4.9 ± 2.6 4.2 ± 2.4           t = 1.35,   p =0.2476 
HAQ, mean ± SD 0.79 ± 0.68 0.79 ± 0.56           t = 0.00,   p =0.9790 
BASDAI, mean ± SD 6.1 ± 1.9 5. 6 ± 2.1  t = 1.22,   p = 0.2720 
ASDAS-PCR, mean ± SD 3.00 ± 0.59 2.94 ± 0.50 t = 0.29,   p =0.5933 
Significant p values are reported in bold face. AS: ankylosing spondylitis, PsA: psoriatic arthritis, ESR: 
erythrocyte sedimentation rate, CRP: C-reactive protein, DAS: Disease Activity Score, BASMI: Bath 
Ankylosing Spondylitis Metrology Index, BASFI: Bath Ankylosing Spondylitis Functional Index, HAQ: 
Health Assessment Questionnaire, BASDAI: Bath Ankylosing Spondylitis Disease Activity Index, 
ASDAS: Ankylosing Spondylitis Disease Activity Score, SD: Standard Deviation. 
 
 
 
Patients enrolled in this study attended the Rheumatology Unit of the Department of 
Medicine- University-Hospital of Padova (Italy). Patients who not responded to 
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NSAIDs or DMARDS were treated with anti- TNFα agents. In those patients who did 
not respond to the first anti- TNFα drug, another one, or in certain cases, more than one 
anti- TNFα agent was switched. Table 8 shows the number (and percentage) of patients 
treated with an anti- TNFα drug, and the type of administered drug. At enrollment, 58 
patients (63.7%) were under therapy with anti- TNFα agents; of these 11 (19%) 
experienced in their clinical history, before enrollment, at least one switch of TNF-α 
drug inhibitor. The number of AS patients treated with a TNF-α inhibitor was higher 
with respect to the treated PsA patients. Most of patients affected by AS were under 
treatment with infliximab, while patients affected by PsA were treated with 
adalimumab.  
 
Table 8. Treatment with anti-TNFα agents: patients affected by AS and PsA at enrollement. 
 AS (n=36) PsA (n=55) 
Therapy with anti- TNFα agents, n (%) 30 (83.3) 28  (50.9) 
Adalimumab, n (%) 6   (20) 15  (53.6) 
Etanercept, n (%) 4   (13.3) 7    (25) 
Golimumab, n (%) 0   (0) 1    (3.6) 
Infliximab, n (%) 20 (66.7) 5     (17.8) 
AS: ankylosing spondylitis, PsA: psoriatic arthritis, n: number. 
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4.3 Haematological and biochemical indices in SpA patients: 
differences in polymorphonuclear cells number and ALT levels in 
patients affected by PsA  
Table 9 reports the mean and standard deviation of haematological and biochemical 
parameters evaluated in controls and in SpA patients at enrollment. The number of 
polymorphonuclear cells (PMN) were higher in SpA patients with respect to controls, 
being the highest values recorded among PsA, which also had significantly higher 
levels of ALT with respect to controls. Serum levels of prealbumin were lower among 
SpA patients than in controls, although the differences were not powerful enough to 
reach the statistical significance. 
 
 
Table 9. Haematological and biochemical parameters in controls, AS and PsA patients at study 
enrollement. 
 Controls (n=223) AS (n=36) PsA (n=55) Statistics 
WBC (x103/µL) 6.11 ± 1.42 6.9475 ± 1.85 7.09 ± 2.02 F= 2.68, p=0.0728 
Haemoglobin (g/L)  144.60 ± 12.8 144.03 ± 12.68 143.87 ± 13.62 F= 0.09, p=0.9162 
Platelets (x103/µL)  236.5 ± 46.0 243.22 ± 63.89 252.21 ± 60.32 F= 2.17, p=0.1162 
PMN (x103/µL)  3.32 ± 1.05 3.90 ± 1.33* 3.98 ± 1.55 ** F= 9.02, p=0.0002 
Monocyte (x103/µL)  0.43 ± 0.35 0.51 ± 0.17 1.01 ± 4.26 F= 2.28, p= 0.1036 
Lymphocyte(x103/µL) 1.90 ± 1.90 2.15 ± 0.84 2.24 ± 0.75 F= 1.12, p= 0.3289 
Glucose (mmol/L) 4.71 ± 0.92 4.88 ± 0.66 4.92 ± 0.79 F= 1.61, p= 0.2014 
Creatinine (µmol/L) 76.97 ± 12.39 76.97 ± 15.50 74.27 ± 17.78 F= 0.86, p= 0.4228 
Uric acid (mmol/L) 0.3 ± 0.058 0.31 ± 0.08 0.30 ± 0.08 F= 0.40, p=0.6685 
ALT (U/L) 22.14 ± 8.99 24.46 ± 10.77 29.22 ± 21.49** F=7.35,  p= 0.0008 
Prealbumin (mg/L)  287.1 ± 46.1 273.63 ± 50.63 273.25 ± 44.55 F=2.79,  p= 0.0630 
CRP (mg/L) 3.49 ± 4.04 6.23 ± 6.65** 5.03 ± 4.54 F=7.20,  p=0.0009 
Haematological and biochemical parameters are reported in terms of mean ± standard deviation. 
Bonferroni’s test for pairwise comparisons: *=p<0.05 with respect to controls; **=p<0.005 with respect 
to controls. Significant p values are reported in bold face. AS: ankylosing spondylitis, PsA: psoriatic 
arthritis, WBC: white blood cells, PMN: polymorphonuclear cells, ALT: alanine transaminase, CRP: C-
reactive protein. 
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4.4 Genetics associations in Spondyloarthritis 
The genetic basis of SpA is complex and includes, in addition to the well established 
HLA-B27 haplotype for AS, a number of variants in genes encoding for inflammatory 
and immunomodulatory cytokines and for their receptors, in genes of the HLA region 
and in genes, like CARD9, involved in the inflammasome. These data come mainly 
from GWASs and requires validation before the potential use in the clinical setting. In 
this study we investigated the presence of association between SpA and any of the 
following genes: two HLA haplotypes, namely HLA-B27 and HLA-CW6; genes 
involved in the TNF pathway, namely TNFA and TNFRSF1A; a gene involved in the 
inflammasome pathway, MEFV. The HLA-B27, HLA-CW6, and five SNPs in the 
promoter region of TNFA, involved in transcription regulation were specifically 
studied. Differently from these common variants, TNFRSF1A and MEFV may affect 
protein function by the presence of uncommon variants. For this reason with the aim to 
identify any potentially relevant sequence variation, the complete sequence analysis of 
exons 2, 3, 4 and 6 of TNFRSF1A gene and of exons 2, 3, 5 and 10 of MEFV gene were 
performed. We selected the above reported exons because they are those described to 
carry hotspot mutations more frequently. All above described genes were analysed in all 
SpA patients. HLA-B27 and TNFA promoter polymorphisms were analysed in all 
controls. HLA-CW6, MEFV and TNFRSF1A sequence analysis were performed in an 
exploratory cohort of controls (n=27). After interim analysis, those variants found to be 
of potential significance were subsequently analysed in all control series.  
 	  	  	  	  	  	  	  	  	  	  	  	  	  
	  	   48 
4.4.1 HLA-B27, not HLA-CW6 haplotype, associates with Ankylosing Spondylitis  
The results of HLA-B27 haplotype in patients and controls are shown in Table 10. The 
frequency of patients carrying the HLA-B27 haplotype was significantly higher than in 
controls (χ2= 120.12, p< 0.0001), being this haplotype mainly associated with AS than 
with PsA.  
 
 
Table 10. HLA-B27 haplotype in controls and in AS and PsA patients. 
Controls (n=214) AS (n=36) PsA (n=55) 
Number 
(frequency, %) 
Number 
(frequency, %) 
χ2, p Number 
(frequency, %) 
χ2, p 
Carriers 
9 
(4.21) 
Non carriers 
205 
(95.79) 
Carriers 
26 
(72.22) 
Non carriers 
10 
(27.78) 
χ2= 118.41 
p<0.0001* 
Carriers 
7 
(12.73) 
Non carriers 
48 
(87.27 
χ2= 5.68 
p=0.051* 
Bonferroni’s test for pairwise comparisons: **Bonferroni’s adjusted p value with respect to controls. 
Significant p values are reported in bold face. The determination of HLA-B27 haplotype was not possible 
in 9 subjects for depletion of biological material. AS: ankylosing spondylitis, PsA: psoriatic arthritis. 
 
 
The results of HLA-CW6 haplotype in patients and controls are shown in Table 11. 
Although a slightly higher frequency of HLA-CW6 carriers was observed among 
patients with AS (about 6%) or PsA (about 13%) with respect to controls (about 4%), 
the difference was not statistically significant (χ2= 2.57, p= 0.277) and for this reason 
the analysis of HLA-CW6 was not extended to the remaining controls. 
 
 
Table 11. HLA-CW6 haplotype in controls and in AS and PsA patients. Results from the 
exploratory study. 
Controls (n=27) AS (n=36) PsA (n=55) 
Number 
(frequency, %) 
Number 
(frequency, %) 
Number 
(frequency, %) 
Carriers 
1 
(3.70) 
Non carriers 
26 
(96.30) 
Carriers 
2 
(5.56) 
Non carriers 
34 
(94.44) 
Carriers 
7 
(12.96) 
Non carriers 
48 
(87.04) 
AS: ankylosing spondylitis, PsA: psoriatic arthritis. 
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4.4.2 TNFA genetic: a risk factor for Spondyloarthritis  
4.4.2.1 TNFA -1031C/-308G haplotype reduces AS risk 
Table 12 reports the results of the genotype discrimination of five SNPs (TNFA -1031 
T>C, -857C>T -376G>A -308G>A -238G>A), in the promoter region of TNFA gene. 
Considering each studied SNP, the Minor Allele Frequency (MAF), the number and 
frequency of genotypes in patients (divided on the basis of diagnosis) and controls are 
shown. The polymorphisms were all in Hardy-Weinberg equilibrium (p >0.01). None of 
the studied TNFA SNPs was singly associated with AS or PsA diagnosis. 
 
 
Table 12. TNFA gene polymorphisms in controls and in AS and PsA patients. 
dbSNP 
(TNFA 
gene) 
MAF Controls (n=223) AS (n=36) PsA (n=55) χ2, p 
GENOTYPES 
Number 
(frequency) 
GENOTYPES 
Number 
(frequency) 
GENOTYPES  
Number 
(frequency) 
-1031T>C 
rs1799964 
C 
(0.263) 
C/C 
8 
(0.09) 
T/C 
62 
(0.41) 
T/T 
63 
(0.50) 
C/C 
1 
(0.03) 
T/C 
10 
(0.28) 
T/T 
25 
(0.69) 
C/C 
4 
(0.06) 
T/C 
20 
(0.38) 
T/T 
31 
(0.56) 
χ2= 6.37 
p= 0.17 
-857C>T 
rs1799724 
T 
(0.208) 
T/T 
10 
(0.04) 
C/T 
66 
(0.32) 
C/C 
142 
(0.64) 
T/T 
3 
(0.05) 
C/T 
10 
(0.35) 
C/C 
23 
(0.60) 
T/T 
2 
(0.06) 
C/T 
22 
(0.37) 
C/C 
29 
(0.57) 
χ2= 3.69 
p= 0.45 
 
-376G>A 
rs1800750 
 
A 
(0.021) 
A/A 
0 
(-) 
G/A 
9 
(0.06) 
G/G 
149 
(0.94) 
A/A 
0 
(-) 
G/A 
0 
(-) 
G/G 
36 
(1) 
A/A 
0 
(-) 
G/A 
1 
(0.02) 
G/G 
47 
(0.98) 
χ2= 3.04 
p= 0.22 
 
-308G>A 
rs1800629 
 
A 
(0.107) 
A/A 
2 
(0.01) 
G/A 
41 
(0.19) 
G/G 
172 
(0.80) 
A/A 
0 
(-) 
G/A 
6 
(0.16) 
G/G 
30 
(0.84) 
A/A 
0 
(-) 
G/A 
14 
(0.25) 
G/G 
39 
(0.75) 
χ2= 2.51 
p= 0.64 
 
-238G>A 
rs361525 
 
A 
(0.044) 
A/A 
0 
(-) 
G/A 
18 
(0.09) 
G/G 
188 
(0.91) 
A/A 
0 
(-) 
G/A 
1 
(0.03) 
G/G 
35 
(0.97) 
A/A 
1 
(0.00) 
G/A 
5 
(0.12) 
G/G 
49 
(0.88) 
χ2= 5.10 
p= 0.20 
The analysis was not performed, because of biological material depletion, in: 133 controls for -1031 T>C 
SNP, 5 controls for -857C>T SNP, 65 controls for -376G>A SNP, 8 controls for -308G>A SNP and 17 
controls for -238G>A SNP. AS: ankylosing spondylitis, PsA: psoriatic arthritis, dbSNP: Single 
Nucleotide Polymorphism Database, TNFA: Tumor Necrosis Factor α, MAF: minor allele frequency. 
 
 
The studied polymorphisms of the TNFA gene, all closely located in the promoter 
region, are carried as different haplotypes. Therefore the haplotypes resulting from the 
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pairwise combination of TNFA-1031T>C, -857C>T, -376G>A, -308G>A and -238G>A 
polymorphisms were inferred by statistical analysis. Table 13 reports the haplotypes 
combinations with their respective frequencies inferred from control subjects.  
 
Table 13.  TNFA haplotypes combinations: frequencies inferred from controls. 
SNPs  SNPs TNFA haplotypes Frequencies (%) 
-1031T>C -857C>T 
-1031T/-857C 49.19 
-1031C/-857C 30.21 
-1031T/-857T 20.60 
-1031C/-857T <0.6 
-1031T>C -376G>A 
-1031T/-376G 69.55 
-1031C/-376G 27.59 
-1031C/-376A 2.86 
-1031T/-376A <0.6 
-1031T>C -308G>A 
-1031T/-308G 59.19 
-1031C/-308G 30.77 
-1031T/-308A 10.04 
-1031C/-308A <0.6 
-1031T>C -238G>A 
-1031T/-238G 70.98 
-1031C/-238G 22.14 
-1031C/-238A 6.88 
-1031T/-238A <0.6 
-857C>T -376G>A 
-857C/-376G 76.52 
-857C/-376A 2.88 
-857T/-376G 2.06 
-857T/-376A <0.6 
-857C>T -308G>A 
-857C/-308G 69.38 
-857T/-308G 20.60 
-857C/-308A 10.01 
-857T/-308A <0.6 
-857C>T -238G>A 
-857C/-238G 72.56 
-857T/-238G 20.61 
-857C/-238A 6.84 
-857T/-238A <0.6 
-308G>A -376G>A 
-308G/-376G 86.98 
-308A/-376G 10.04 
-308G/-376A 2.98 
-308A/-376A <0.6 
-308G>A -238G>A 
-308G/-238G 83.10 
-308A/-238G 10.05 
-308G/-238A 6.85 
-308A/-238A <0.6 
-238G>A -376G>A 
-238G/-376G 93.18 
-238A/-376G 4.30 
-238A/-376A 2.52 
-238G/-376A <0.6 
SNP: Single Nucleotide Polymorphism, TNFA: Tumor Necrosis Factor α. 
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To verify whether any TNFA haplotype exerts any independent role over SpA 
diagnosis, logistic regression analyses were performed, on considering SpA diagnosis as 
the outcome variable and TNFA haplotype combinations as predictors. Table 14 reports 
the results of the analyses. For any combination the reference haplotype was the most 
frequent among controls (Table 13). The possible pairwise combinations between 
TNFA SNPs were ten and the overall seventeen haplotypes were inferred. The OR with 
95% confidence intervals (CI) with respect to the reference haplotype are shown.  
Only the TNFA -1031C/-308G haplotype was significantly associated with SpA 
(p<0.05), with an OR lower than 1, this suggesting its protective role. 	  	  
Table 14.  Logistic regression analysis considering SpA diagnosis as the outcome variable and 
TNFA haplotype combinations as predictors. 
SNP  SNP Reference TNFA haplotype 
Risk TNFA 
haplotype OR (95% CI) p 
-1031T>C -857C>T -1031T/-857C 
-1031C/-857C 0.66 (0.41 - 1.04) 0.073 
-1031T/-857T 1.02 (0.67 - 1.58) 0.916 
-1031C/-857T - - 
-1031T>C -376G>A -1031T/-376G 
-1031C/-376G 0.71 (0.45 - 1.11)  0.133 
-1031C/-376A - - 
-1031T/-376A - - 
-1031T>C -308G>A -1031T/-308G 
-1031C/-308G 0.63 (0.40 - 0.99) 0.047 
-1031T/-308A 1.00 (0.57 - 1.75) 0.998 
-1031C/-308A - - 
-1031T>C -238G>A -1031T/-238G 
-1031C/-238G 0.80 (0.50 - 1.29) 0.362 
-1031C/-238A - - 
-1031T/-238A - - 
-857C>T -376G>A -857C/-376G 
-857C/-376A 0.21 (0.03 - 1.68) 0.141 
-857T/-376G 1.16 (0.77 - 1.74) 0.483 
-857T/-376A - - 
-857C>T -308G>A -857C/-308G 
-857T/-308G 1.21 (0.80 - 1.83) 0.357 
-857C/-308A 1.19 (0.68 - 2.08) 0.536 
-857T/-308A - - 
-857C>T -238G>A -857C/-238G 
-857T/-238G 1.16 (0.77 - 1.74) 0.487 
-857C/-238A 0.65 (0.29 - 1.43) 0.284 
-857T/-238A - - 
-308G>A -376G>A -308G/-376G 
-308A/-376G 1.10 (0.64 - 1.91) 0.722 
-308G/-376A 0.20 (0.03 - 1.57) 0.125 
-308A/-376A - - 
-308G>A -238G>A -308G/-238G 
-308A/-238G 1.04 (0.60 - 1.81) 0.888 
-308G/-238A 0.47 (0.19 - 1.14) 0.095 
-308A/-238A - - 
-238G>A -376G>A -238G/-376G 
-238A/-376G 0.82 (0.33 - 2.02) 0.661 
-238A/-376A - - 
-238G/-376A - - 
Significant p values are reported in bold face. SNP: Single Nucleotide Polymorphism, TNFA: Tumor 
Necrosis Factor α, OR: Odds Ratio, CI: Confidence Interval.  
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The identified TNFA -1031C/-308G haplotype was confirmed to be a protective factor 
for AS, not for PsA, at logistic regression analysis performed comparing controls to 
these two diseases separately (Table 15).  
 
 
 
Table 15.  Logistic regression analysis considering AS or PsA diagnosis as the outcome 
variable and the 1031T>C/308G>A SNPs combination as predictor. 
   AS PsA 
Reference 
haplotype 
Risk haplotype Controls OR  
(95% CI) 
p OR  
(95% CI) 
p 
-1031T/-308G 
-1031C/-308G Ref. - 
0.43  
(0.22 - 0.85) 
0.015 
0.80  
(0.48 - 1.35) 
0.400 
-1031T/-308A Ref. - 
0.66  
(0.27 - 1.60) 
0.354 
1.29  
(0.67 - 2.47) 
0.444 
Significant p values are reported in bold face. AS: ankylosing spondylitis, PsA: psoriatic arthritis, OR: 
Odds Ratio, CI: Confidence Interval.  
 
 
 
The estimated frequencies of the -1031/-308 TNFA haplotypes in controls and in 
patients affected by PsA and AS are also shown in Figure 10. The frequency of the 
TNFA -1031C/-308A haplotype was very low (< 0.6), therefore it was not considered. 
In agreement with findings from logistic regression analyses, the frequency of the 
TNFA -1031C/-308G haplotype was significantly lower in AS patients (17%) than in 
PsA patients (25%) and controls (31%) (χ2= 14.50 and p = 0.0059).   
 
 
 
Figure 10. Frequency of haplotypes derived from the TNFA-1031T>C/-308G>A SNPs 
combination. *p < 0.05 
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By combining the two SNPs -1031T>C and -308G>A of the TNFA gene, the six 
following genotypes were also inferred: TG/TG, TG/TA, TG/CG, TA/TA, CG/TA, 
CG/CG. On the basis of the most frequent TNFA haplotype (-1031T/-308G), genotypes 
were grouped in three categories as follows: homozygous genotype (TG/TG), 
heterozygous genotypes (TG/other), and genotypes identified by rare haplotypes (rare 
haplotypes).  
The frequency of these three categories, in controls and in patients affected by AS and 
PsA are shown in Figure 11.  
 
 
 
 
Figure 11. Frequency of the genotypes derived from the TNFA -1031/-308 haplotypes 
combination in controls and in patients. 
 
 
 
The rare haplotypes were less frequent in patients affected by AS (about 6%) than in 
controls (about 16%) (χ2= 7.47 and p = 0.024). No significant difference was found 
between PsA patients and controls (χ2= 0.29 and p = 0.865). 
Intriguingly, the TNFA -1031/-308 inferred genotypes were associated with HLA-B27. 
Figure 12 shows the frequencies of the three inferred genotypes in HLA-B27 positive 
and negative subjects. 
 
 
 
	  	   54 
 
 
 
Figure 12. Frequency of the genotypes derived from the TNFA -1031/-308 haplotypes 
combination in HLA-B27 positive and negative subjects. *p < 0.05  
 
 
Among HLA-B27 carriers, the rare inferred genotypes were less frequently found than 
in HLA-B27 negative subjects (χ2= 6.24 and p = 0.044). 
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4.4.2.2 TNFA and HLA-B27 haplotypes are closely linked to the risk of developing SpA  
Since TNFA is located in the MHC region of chromosome 6, we verified whether 
haplotypes resulting from the combination of each TNFA SNP and HLA-B27 might 
affect SpA risk. Table 16 shows the HLA-B27/TNFA haplotypes with their frequencies 
among controls.  
 
Table 16.  HLA-B27/TNFA haplotypes combinations: frequencies inferred from controls. 
HLA-B27/ TNFA SNP TNFA haplotypes Frequencies (%) 
HLA-B27/ -1031T>C 
HLA-B27 neg/ -1031T 69.04 
HLA-B27 neg/ -1031C 28.65 
HLA-B27 pos/ -1031C 2.31 
HLA-B27 pos/ -1031T <0.6 
HLA-B27/ -857C>T 
HLA-B27 neg/ -857C 77.87 
HLA-B27 neg/ -857T 19.96 
HLA-B27 pos/ -857C 1.53 
HLA-B27 pos/ -857T 0.64 
HLA-B27/ -376G>A 
HLA-B27 neg/ -376G 94.95 
HLA-B27 neg/ -376A 2.90 
HLA-B27 pos/ -376G 2.15 
HLA-B27 pos/ -376A <0.6 
HLA-B27/ -308G>A 
HLA-B27 neg/ -308G 88.10 
HLA-B27 neg/ -308A 9.74 
HLA-B27 pos/ -308G 1.86 
HLA-B27 pos/ -308A <0.6 
HLA-B27/ -238G>A 
HLA-B27 neg /-238G 9.10 
HLA-B27 neg /-238A 6.87 
HLA-B27 pos /-238G 2.10 
HLA-B27 pos /-238A <0.6 
SNP: Single Nucleotide Polymorphism, TNFA: Tumor Necrosis Factor α,  
ΗLA: human leukocyte antigen. 
 
 
A logistic regression analysis was then performed considering SpA diagnosis as the 
outcome variable, and HLA-B27/TNFA haplotypes as predictor variables. The obtained 
results, reported in terms of OR with 95% CI with respect to the reference haplotype 
(that most frequent among controls), are shown in Table 17. 
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Table 17.  Logistic regression analysis considering SpA diagnosis as the outcome variable, and 
the HLA-B27/TNFA haplotypes as predictors. 
HLA-B27/ TNFA 
SNP 
Reference haplotype Risk haplotype OR (95% CI) p 
HLA-B27 neg HLA-B27 pos 12.96 (5.87 – 28.63) <0.0001 
HLA-B27/ -1031T>C HLA-B27 neg/ -1031T 
HLA-B27 neg/ -1031C 0.80 (0.49 - 1.31) 0.377 
HLA-B27 pos/ -1031C - - 
HLA-B27 pos/ -1031T - - 
HLA-B27/ -857C>T HLA-B27 neg/ -857C 
HLA-B27 neg/ -857T 1.14 (0.70 - 1.84) 0.608 
HLA-B27 pos/ -857C 10.42 (3.75 -28.93) <0.0001 
HLA-B27 pos/ -857T 9.88 (1.53 - 63.65) 0.016 
HLA-B27/ -376G>A HLA-B27 neg/ -376G 
HLA-B27 neg/ -376A 0.24 (0.03 - 1.95) 0.183 
HLA-B27 pos/ -376G 9.86 (4.61 - 21.10) <0.0001 
HLA-B27 pos/ -376A - - 
HLA-B27/ -308G>A HLA-B27 neg/ -308G 
HLA-B27 neg/ -308A 1.40 (0.81- 2.43) 0.232 
HLA-B27 pos/ -308G 10.53 (4.90 - 22.60) <0.0001 
HLA-B27 pos/ -308A - - 
HLA-B27/ -238G>A HLA-B27 neg /-238G 
HLA-B27 neg /-238A 0.75 (0.34 - 1.66) 0.480 
HLA-B27 pos /-238G 10.13 (4.73-21.70) <0.0001 
HLA-B27 pos /-238A - - 
Significant p values are reported in bold face. SNP: Single Nucleotide Polymorphism, TNFA: Tumor 
Necrosis Factor α, ΗLA: human leukocyte antigen, AS: ankylosing spondylitis, PsA: psoriatic arthritis.  	  
 
 
HLA-B27 appeared to have a dominant effect on SpA risk, independently from its 
combined haplotype with any single TNFA SNP. 
The logistic regression analysis was performed also considering the differential 
diagnosis, AS and PsA. Results are reported in Table 18.    
Among the studied combinations, three haplotypes were significantly associated with 
the risk of AS as well as of PsA: HLA-B27 positive/-376G, HLA-B27 positive/-308G 
and HLA-B27 positive/-238G. The TNFA -376G, -308G, -238G alleles, not only singly 
(Table 18), but also when inherited all together with HLA-B27 haplotype, significantly 
enhance the risk of developing PsA (OR: 3.298; CI: 1.193-9.115; p=0.021) and AS 
(OR: 25.895; CI: 11.324-59.213; p<0.0001). Differently from the PsA group, in the AS 
group in addition to the three already mentioned haplotypes, the HLA-B27 positive/-
857C haplotype was also significantly associated to the risk of developing the disease. 
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Table 18. Logistic regression analysis considering AS or PsA diagnosis as the outcome 
variable, and HLA-B27 alone or combined with TNFA SNPs in haplotypes as predictors. 
 AS PsA 
HLA-B27/ 
TNFA 
SNP 
Reference 
haplotype 
Risk haplotype 
OR 
(95% CI) 
p 
OR 
(95% CI) 
p 
HLA-B27 neg HLA-B27 pos 
57.78  
(21.49 - 155.32) 
<0.0001 
3.24   
(1.15- 9.14) 
0.026 
HLA-B27/ 
-1031T>C 
HLA-B27 neg/ 
-1031T 
HLA-B27 neg/ 
-1031C 
0.58 
(0.23 -1.47) 
0.252 
0.87 
(0.52 -1.48) 
0.616 
HLA-B27 pos/ 
-1031C 
- - - - 
HLA-B27 pos/ 
-1031T 
- - - - 
HLA-B27/ 
-857C>T 
HLA-B27 neg/ 
-857C 
HLA-B27 neg/ 
-857T 
1.14 
(0.54 - 2.38) 
0.733 
1.20 
(0.70 - 2.06) 
0.500 
HLA-B27 pos/ 
-857C 
25.48 
(10.89 - 59.59) 
<0.0001 
2.80 
(0.63 - 12.43) 
0.176 
HLA-B27 pos/ 
-857T 
- - 
4.13 
(0.40 - 42.31) 
0.232 
HLA-B27/ 
-376G>A 
HLA-B27 neg/ 
-376G 
HLA-B27 neg/ 
-376A 
7.11e-07 (-) 0.989 
0.37 
(0.05 - 2.98) 
0.351 
HLA-B27 pos/ 
-376G 
24.97 
(11.03 - 56.54) 
<0.0001 
3.04 
(1.10 - 8.35) 
0.031 
HLA-B27 pos/ 
-376A 
- - - - 
HLA-B27/ 
-308G>A 
HLA-B27 neg/ 
-308G 
HLA-B27 neg/ 
-308A 
1.31 
(0.53 - 3.24) 
0.556 
1.44 
(0.77 - 2.71) 
0.258 
HLA-B27 pos/ 
-308G 
26.63 
(11.67 - 60.79) 
<0.0001 
3.24 
(1.18 - 8.95) 
0.023 
HLA-B27 pos/ 
-308A 
- - - - 
HLA-B27/ 
-238G>A 
HLA-B27 neg / 
-238G 
HLA-B27 neg / 
-238A 
0.29 
(0.04 - 2.20) 
0.233 
0.97 
(0.42 - 2.24) 
0.936 
HLA-B27 pos / 
-238G 
25.00 
(11.03 - 56.68) 
<0.0001 
3.16 
(1.15-8.69) 
0.026 
HLA-B27 pos / 
-238A 
- - - - 
Significant p values are reported in bold face. AS: ankylosing spondylitis, PsA: psoriatic arthritis SNP: 
Single Nucleotide Polymorphism, TNFA: Tumor Necrosis Factor α, ΗLA: human leukocyte antigen.  	  
 
With respect to the reference haplotype, only two further haplotypes were inferred from 
the combination of HLA-B27 and TNFA SNP -376G>A, -308G>A and -238G>A, 
being the frequent TNFA allele associated with positive HLA-B27, while the rare 
alleles with negative HLA-B27. By contrast HLA-B27 resulted in more haplotypes with 
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TNFA -857C>T SNP. The haplotype HLA-B27 positive/TNFA -857C only being 
correlated with AS diagnosis and this was confirmed by the analysis of HLA-
B27/TNFA-857 haplotypes frequencies found in the different diseases in comparison 
with controls (Figure 13) (χ2= 52.82 and p < 0.0001).  
 
 
 
 
Figure 13. Frequency of the HLA-B27/TNFA-857 haplotypes in controls and in patients.  
***p < 0.0001 
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4.4.3 TNFRSF1A gene variants do not associate with Spondyloarthritis 
By the DHPLC screening of exons 2, 3, 4 and 6 of the TNFRSF1A gene followed by 
direct sequence analysis of positive samples, a total of three polymorphisms were 
identified during the explorative study and, among them, only the R92Q and the 
c.625+10A>G were selected for their potential functional implications (Table 19). MAF 
were 0.034 and 0.483 respectively. Both SNPs were not correlated with the presence of 
SpA (χ2 = 1.073 and p = 0.300 for R92Q; χ2= 4.721 and p= 0.094 for c.625+10A>G). 
Therefore the study of these gene variations was not extended to the entire number of 
controls. 
 
 
Table 19. TNFRSF1A gene polymorphisms in controls and patients (AS and PsA). 
Results from the exploratory study. 
dbSNP 
TNFRSF1A 
gene 
MAF Controls (n=27) AS (n=36)  PsA (n=55)  
χ2, p GENOTYPES 
Number 
(frequency) 
GENOTYPES 
Number 
(frequency) 
GENOTYPES  
Number 
(frequency) 
R92Q 
c.362G>A 
rs4149584 
A 
(0.034) 
A/A 
0 
(-) 
G/A 
3  
(0.11) 
G/G 
24 
(0.89) 
A/A 
0 
(-) 
G/A 
2  
(0.05) 
G/G 
34 
(0.95) 
A/A 
0 
(-) 
G/A 
3  
(0.05) 
G/G 
52 
(0.95) 
χ2= 1.04 
p= 0.60 
c.625+10A>G 
rs1800693 
G 
(0.483) 
G/G  
4 
(0.25) 
G/A 
19 
(0.50) 
A/A 
4 
(0.25) 
G/G  
8 
(0.20) 
G/A 
16 
(0.49) 
A/A 
12 
(0.31) 
G/G  
14 
(0.25) 
G/A 
27 
(0.50) 
A/A 
14 
(0.25) 
χ2= 5.22 
p= 0.27 
AS: ankylosing spondylitis, PsA: psoriatic arthritis, dbSNP: Single Nucleotide Polymorphism Database, 
TNFRSF1A: Tumor Necrosis Factor Receptor Superfamily Member 1A, MAF: minor allele frequency.  
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4.4.4 MEFV gene variants do not associate with Spondyloarthritis 
In the exploratory study, direct sequencing of exons 2, 3, 5 and 10 of MEFV gene 
allowed the identification of a total of twenty-one SNPs. Among them, eleven were 
synonymous base substitutions (exon 2: D102D, A165A, G138G; exon 3: R314R; exon 
5: E474E, D510D, Q476Q, R501R, Q489Q; exon 10: F721F, P706P), and therefore 
they were not considered in the subsequent statistical analyses. The remaining ten 
variants (exon 2: E148Q, S179N, R202Q; exon 3: P369S, R408Q, R348H; exon 5: 
A457V; exon 10: A744S; K695M, M680IGA) were missense SNPs of potential 
functional significance and their genotypes with minor alleles frequencies are reported 
in Table 20.   
The variant alleles of almost all the identified missense SNPs were extremely rare in our 
population, being their MAF lower or equal to 0.025 for nine out of ten SNPs. The 
R202Q SNP had a MAF of 0.336 and the rare homozygous AA genotype was found 
only among AS or PsA patients, not in controls, although the difference was not 
statistically significant. Since this might be dependent on the low number of AS and 
PsA cases with the rare genotype, we performed the statistical analysis by comparing 
SpA overall with controls, and this was significant (χ2 = 7.4837; p= 0.006). 
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Table 20. MEFV gene polymorphisms in controls and in patients (AS and PsA). 
Results from the exploratory study. 
dbSNP 
MEFV gene 
MAF Controls (n=27) AS (n=36)  PsA (n=55) χ2, p 
GENOTYPES 
Number 
(frequency) 
GENOTYPES 
Number 
(frequency) 
GENOTYPES  
Number 
(frequency) 
R202Q 
c.605G>A 
rs224222 
A 
(0.288) 
A/A 
0 
(-) 
G/A 
13 
(0.42) 
G/G 
14 
(0.58) 
A/A 
2 
(0.09) 
G/A 
17 
(0.41) 
G/G 
17 
(0.50) 
A/A 
6 
(0.10) 
G/A 
22 
(0.43) 
G/G 
27 
(0.48) 
χ2= 2.37 
p= 0.67 
S179N 
c.536G>A 
A 
(0.004) 
A/A 
0 
(-) 
G/A 
0 
(-) 
G/G 
27 
(1.00) 
A/A 
0 
(-) 
G/A 
1 
(0.03) 
G/G 
35 
(0.97) 
A/A 
0 
(-) 
G/A 
0 
(-) 
G/G 
55 
(1.00) 
χ2= 2.30 
p= 0.32 
E148Q 
c.442G>C 
rs3743930 
C 
(0.013) 
C/C 
0 
(-) 
G/A 
0 
(-) 
G/G 
27 
(1.00) 
C/C 
0 
(-) 
G/C 
1 
(0.03) 
G/G 
35 
(0.97) 
C/C 
0 
(-) 
G/C 
2 
(0.04) 
G/G 
53 
(0.96) 
χ2= 0.98 
p= 0.61 
P369S 
c.1105C>T 
rs11466023 
T 
(0.025) 
T/T 
1 
(0.01) 
C/T 
1 
(0.10) 
C/C 
25 
(0.89) 
T/T 
0 
(-) 
C/T 
0 
(-) 
C/C 
36 
(1.00) 
T/T 
0 
(-) 
C/T 
3 
(0.05) 
C/C 
52 
(0.95) 
χ2= 5.39 
p= 0.25 
R408Q 
c.1223G>A 
rs11466024 
A 
(0.017) 
A/A 
0 
(-) 
G/A 
1 
(0.04) 
G/G 
26 
(0.96) 
A/A 
0 
(-) 
G/A 
0 
(-) 
G/G 
36 
(1.00) 
A/A 
0 
(-) 
G/A 
3 
(0.05) 
G/G 
52 
(0.95) 
χ2= 1.99 
p= 0.37 
R348H 
c.1043G>A 
rs104895198 
 
A 
(0.004) 
A/A 
0 
(-) 
G/A 
0 
(-) 
G/G 
27 
(1.00) 
A/A 
0 
(-) 
G/A 
0 
(-) 
G/G 
36 
(1.00) 
A/A 
0 
(-) 
G/A 
1 
(0.02) 
G/G 
54 
(0.98) 
χ2= 1.16 
p= 0.56 
A457V 
c.1370C>T 
rs104895151 
T 
(0.004) 
T/T 
0 
(-) 
C/T 
0 
(-) 
C/C 
27 
(1.00) 
T/T 
0 
(-) 
C/T 
0 
(-) 
C/C 
36 
(1.00) 
T/T 
0 
(-) 
C/T 
1 
(0.02) 
C/C 
54 
(0.98) 
χ2= 1.15 
p= 0.56 
A744S 
c.2230G>T 
rs61732874 
T 
(0.004) 
T/T 
0 
(-) 
G/T 
0 
(-) 
G/G 
27 
(1) 
T/T 
0 
(-) 
G/T 
0 
(-) 
G/G 
36 
(1.00) 
T/T 
0 
(-) 
G/T 
1 
(0.02) 
G/G 
54 
(0.98) 
χ2= 1.15 
p= 0.56 
K695M 
c.2084A>T 
rs104895129 
T 
(0.008) 
T/T 
0 
(-) 
A/T 
1 
(0.04) 
A/A 
26 
(0.96) 
T/T 
0 
(-) 
A/T 
1 
(0.03) 
A/A 
35 
(0.97) 
T/T 
0 
(-) 
A/T 
0 
(-) 
A/A 
55 
(1.00) 
χ2= 1.86 
p= 0.40 
M680IGA 
c.2040G>A 
rs28940580 
A 
(0.004) 
A/A 
0 
(-) 
G/A 
0 
(-) 
G/G 
27 
(1.00) 
A/A 
0 
(-) 
G/A 
0 
(-) 
G/G 
36 
(1.00) 
A/A 
0 
(-) 
G/A 
1 
(0.02) 
G/G 
54 
(0.98) 
χ2= 1.15 
p= 0.56 
AS: ankylosing spondylitis, PsA: psoriatic arthritis, dbSNP: Single Nucleotide Polymorphism Database, 
MEFV: Mediterranean fever, MAF: minor allele frequency. 
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To confirm this result, i.e. the association between R202Q SNP and SpA, the study of 
this SNP was extended to the entire controls population (Table 21). The frequency of 
the rare homozygous genotype AA, was very similar in patients (0.09) and in controls 
(0.07) and the difference was not statistically significant. Therefore the study extended 
to a higher number of controls does not confirm the association between SpA diagnosis 
and R202Q SNP.  
 
 
 
Table 21. R202Q polymorphism in the entire studied population.  
Gene dbSNP MAF SpA (n=91)  Controls (n=218) χ2, p 
GENOTYPES 
Number 
(frequency) 
GENOTYPES  
Number 
(frequency) 
MEFV R202Q 
c.605G>A 
rs224222 
A 
(0.272) 
A/A 
8 
(0.09) 
G/A 
39 
(0.42) 
G/G 
44 
(0.49) 
A/A 
15 
(0.07) 
G/A 
83 
(0.38) 
G/G 
120 
(0.55) 
χ2= 1.05 
p= 0.59 
The determination of R202Q SNP was not possible in 5 subjects for depletion of biological material. 
SpA: Spondyloarthritis, dbSNP: Single Nucleotide Polymorphism Database, MEFV: Mediterranean 
fever, MAF: minor allele frequency.  	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4.4.5 TNFRSF1A c.625+10A>G SNP associates with effective anti-TNFα treatment 
in SpA 
On the basis of the previously reported results, we verified whether HLA-B27 and 
TNFA genetics correlate with response to anti-inflammatory treatment. 
Patients were classified in two groups, on the basis of the time to reach a BASDAI 
score lower than or equal to 4 (response time). Patients with a BASDAI score lower 
than/equal to 4 were regarded as having no active disease. To evaluate the response to 
treatment the selected target was 10 months from the starting of therapy. Patients were 
subdivided in two groups on the basis of their response to therapy at 10 months after 
starting the last therapy: Group 1= BASDAI score lower than/equal to 4; Group 2= 
BASDAI score higher than 4. Table 22 reports descriptive statistics of Groups 1 and 2. 
Thirty-six of the 65 patients reached a BASDAI score lower than/equal to 4 in a time 
ranging from 1 to 10 months, while the remaining 29 in a timeframe spanning from 12 
and 36 months. 
 
Table 22. Months to reach a BASDAI score lower than/equal to 4 in groups 1 and 2.  
 BASDAI ≤ 4 
Anti-TNFα therapy N of 
SpA patients 
Mean Max Min 50
th 
percentile IQR SD 
Group 1 (≤ 10 months) 36 5.94 10 1 6 0 1.19 
Group 2 (>10 months) 29 16.55 36 12 12 5 7.16 
BASDAI: Bath Ankylosing Spondylitis Disease Activity Index, TNFα: Tumor Necrosis Factor α, SpA: 
Spondyloarthritis, N: number, Max: maximum value (months), Min: minimum value (months), IQR: 
interquartile range, SD: standard deviation. 
 
 
Table 23 reports the number and percentage of patients belonging to group 1 or 2 in 
relation to the identified genotypes in HLA-B27, TNFA and TNFRSF1A genes. 
The TNFRSF1A c.625+10A/G SNP was significantly associated (p = 0.031) with a 
slower response to therapy. No association was found between the response to 
treatments and the other investigated polymorphisms. 
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Table 23. HLA-B27, TNFA and TNFRSF1A genetics in the response to treatment.  
 BASDAI ≤ 4  
≤ 10 months > 10 months 
n (%) n (%) 
HLA-B27 
Negative 22 (33.8%)       20 (30.8%) χ2 =  0.4334    
p = 0.510 Positive 14 (21.5%) 9 (13.8%) 
TNFA 
-1031T>C 
T/T 23 (35.4%)       17 (26.1%) χ2 = 0.1960 
p = 0.907 T/C 11 (16.9%)       10 (15.4%) C/C 2 (3.1%)        2 (3.1%) 
-857C>T 
C/C 22 (34.9%)  16 (25.4%)         χ2 = 4.3876 
p = 0.111 T/C 14 (22.2%)  8 (12.7%)           T/T 0  (0.0%)              3 (4.8%) 
-376G>A 
G/G 34   (55.7%)             26 (42.6%) χ2 = 0.7552 
p = 0.385 
 
G/A 1    (1.6%)              0 (0.0%)              
A/A - - 
-308G>A 
G/G 30   (47.6%)  20 (31.7%)        χ2 = 0.8077 
p = 0.369 G/A 6    (9.5%)  7 (11.1%)        A/A - - 
-238G>A 
G/G 33  (50.8%)  27 (41.5%)        χ2 = 0.0467 
p = 0.829 G/A 3  (4.6%)  2 (3.1%)         A/A - - 
TNFRSF1A 
R92Q (c.362G>A) 
G/G 35 (53.8%) 26 (40%) χ2 = 1.5925 
p = 0.207 G/A 1 (1.5%)        3 (4.6%) A/A - - 
c.625+10A>G 
A/A  13 (20%)        5 (7.7%) 
χ2 = 6.9648 
p = 0.031 G/A 18 (27.7%)       12 (18.5%) 
G/G  5 (7.7%)            12 (18.5%) 
Significant p values are reported in bold face. The analysis was not performed, because of biological 
material depletion, in: 2 patients for -857C>T SNP, 2 patients for -376G>A SNP and 2 patients for -
308G>A SNP. BASDAI: Bath Ankylosing Spondylitis Disease Activity Index, TNFA: Tumor Necrosis 
Factor α, TNFRSF1A: Tumor Necrosis Factor Receptor Superfamily Member 1A.  	  
 
The association between c.625+10A>G polymorphism and response time was verified 
among patients treated with anti-TNFα drugs and confirmed among those treated with 
infliximab but not in those treated with adalimumab (Table 24). The number of patients 
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treated with etanercept or golimumab was too low to support statistical analysis and 
these drugs were therefore not considered in separate analysis. 
 
 
Table 24. c.625 +10 A>G polymorphism in the response to treatment with anti-TNFα therapy.  
c.625+10A>G 
Infliximab Adalimumab 
BASDAI ≤ 4 
Fisher’s 
exact 
BASDAI ≤ 4 
Fisher’s 
exact 
≤ 10 months 
n (%) 
> 10 months 
n (%) 
≤ 10 months 
n (%) 
> 10 months 
n (%) 
A/A 5 (38.5%) 1 (20.0%) 
0.026 
3 (23.1%) 0 (0%) 
1.000 G/A 9 (50.0%) 2 (16.7%) 5 (27.8%) 0 (0%) 
G/G 1 (20.0%) 5 (41.7%) 4 (80%) 1 (8.3%) 
Significant p values are reported in bold face. BASDAI: Bath Ankylosing Spondylitis Disease Activity 
Index 
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5. DISCUSSION and CONCLUSIONS 
 
The SpA are a group of chronic inflammatory diseases characterized by the sharing of 
distinctive pathological, clinical and radiographic aspects and a strong genetic 
predisposition, that leads to the activation of autoinflammation and the dys-regulation of 
the immune-system [3]. The two main distinct and frequent SpA subgroups are AS and 
PsA. 
 In many cases, an early diagnosis and an appropriate monitoring of disease activity 
can be difficult because of the overlap of clinical features. In addition, at least half of 
patients with SpA present indices of inflammation (ESR and CRP) in the normal range, 
even in the presence of clear expression of disease activity. Therefore, unlike 
rheumatoid arthritis and other inflammatory arthropathies, specific biomarkers of 
disease activity are not commonly used in clinical practice both in AS and PsA [11]. 
Among the genetic predisposing factors, a well-known role is that of HLA-B27, which 
contributes however only 20–30% of the total heritability, whereas the whole MHC 
accounts for about 40–50% of the genetic risk of developing SpA. Even the presence of 
HLA-B27, which increases the chance of ultimately diagnosing a SpA especially in the 
context of non-radiographic SpA, cannot be considered sufficient to diagnose the 
condition. Moreover, several SNPs in non-HLA-B genes have been identified as 
associated with AS, and more in general with SpA [2, 4].  
 For all these reasons, much attention is currently devoted to the identification of 
biochemical and genetic biomarkers to be used in the diagnosis as well as prognostic 
factors for evaluating the effectiveness of treatment. Must be remembered that, in these 
patients, a delay in diagnosis (generally estimates in 8-11 years by the symptoms onset) 
and consequently in treatment, imparts a tremendous symptomatic burden and loss of 
function during the productive years of life [10].  
 The present study, conducted in a cohort of 91 SpA patients coming from a North-
East Italian region, was aimed to identify biohumoral and genetic factors to support the 
diagnostic and prognostic (response to therapy) work-up of SpA diseases. In particular, 
in addition to biochemical and haematological indices, we investigated whether SNPs in 
the promoter region of TNFA, or SNPs of the autoinflammatory genes TNFRSF1A and 
MEFV might concur with HLA-B27 in enhancing the risk of developing SpA disease 
and/or in predicting the response to treatment, including anti-TNFα drugs.  
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 Considering the wide variety of expression of these diseases, both from a clinical that 
biohumoral point of view, only the two most prevalent subgroups of SpA patients, AS 
and PsA patients, were recruited in the study. Therefore, patients affected by non-
radiographic axial SpA, ReA, IBD- SpA and uSpA were not enrolled because of their 
very low prevalence among worldwide patients [8] as well as among Italian patients [9]. 
Furthermore, while the AS belongs to the group of axial involvement SpA, PsA is 
representative of the peripheral SpA. The two groups of patients, as expected, were 
well-distinguished by characteristic clinical manifestations. Family history of disease, 
personal history of psoriasis, dactilitys and pheripheral arthritis were more frequently 
found among PsA, and this fit well with the Classification Criteria for Psoriatic Arthritis 
(CASPAR) [41]. Back pain and buttock pain, although commonly shared by the two 
disease groups, were more frequently recorded among patients affected by AS than 
PsA. Some extra-articular clinical manifestations were extremely rare in both groups, 
which, at diagnosis, had very similar scores of outcome, and similar demographic and 
anthropometric characteristics, such as age and BMI. The differences and similarities 
between AS and PsA support the notion that these diseases probably share a common 
background on the one hand, but specific genetic and/or environmental factors dictate 
AS or PsA evolution.  
 We first evaluated whether these two diseases could be distinguished by routinely 
used biochemical and haematological parameters and found that in both diseases a 
higher number of circulating PMN and higher CRP levels could be detected with 
respect to controls, and in PsA higher levels of ALT could be observed with respect not 
only to controls but also to AS. Aspartate aminotransferase is an index of liver injury of 
any cause and in the present series it might indicate the presence of mild liver damage 
due to non-alcoholic fatty liver disease, which is observed mainly in PsA than in AS 
[145, 146]. The mild degree of liver damage was hypothesized because the observed 
ALT levels were never above twice the cut-off. The finding of higher circulating PMN 
and CRP in both PsA and AS deserves some attention. Although both indices were not 
highly elevated and often comprised within the reference intervals, their increased 
levels in SpA suggest that the systemic inflammatory process underlying these diseases 
cannot be completely switch off despite treatment that means, in other words, a 
persisting smouldering inflammatory fire. This conclusion is supported by fact that 
biochemical data were collected at enrollment of patients, when all were under 
treatment with anti-TNFα drugs or NSAIDs/DMARDS. Although the differences in 
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WBC count and CRP levels between patients and controls were statistically significant, 
they cannot be proposed for diagnosis especially in patients under therapy because their 
variations were too light.  
We focused our efforts in evaluating whether genetics could be of some help in this 
setting, taking into care consideration the fact that it is not affected by therapy. We first 
evaluated the association between disease diagnosis and HLA-B27, a genetic paradigm 
for AS [2, 35, 56]. In agreement a strong association between AS diagnosis and HLA-
B27 positivity was found. This genetic predisposing factor was also slightly associated 
with PsA diagnosis, further supporting the notion that HLA-B27 is generally a risk 
factor for different subgroups of SpA [56]. The different degree of association, strong 
for AS and mild for PsA, might be interpreted in the light of the hypothesized roles of 
this leukocyte antigen in SpA pathogenesis. This antigen appears to play a relevant role 
in autoimmunity by the selective presentation of self antigens to immune competent T 
cells, being selectivity potentially dependent on allelic variants of HLA-B27, expression 
of the surface cells of homo- or hetero- HLA-B27 dimers and on a various grade of 
protein misfolding [53, 56-64]. The molecular analysis of HLA-B27 allowed us to 
analyse the presence of the most frequent alleles, but not to distinguish them one from 
another, nor was it able to give us indications about misfolding or dimerization. 
Therefore we might only hypothesize that AS and PsA share in part the common HLA-
B27 genetic background, but their full clinical manifestations depend on more complex 
interplay with other genetic and/or environmental factors.  
HLA-B27 gene belongs to the family of the major histocompatibility complex located 
in the short arm of chromosome 6. The HLA region includes the major genetic risk 
factors for SpA [2, 34, 47] and, in addition to HLA-B27, HLA-CW6 was demonstrated 
to be associated with PsA risk [46- 48]. In our series of patients this variant was more 
frequently found among PsA, than AS or controls, but the difference was not 
statistically significant. This is not surprising since HLA-CW6 was described in 
association with vulgaris psoriasis and our patients had only few cutaneous 
manifestations and onychopathy, and HLA-CW6 was described to account with more 
than other 30 genes only about 20% genetic predisposition to PsA [46, 48]. 
Within the HLA region is located also the TNFA gene, encoding TNF [69, 70]. Due 
to the pathophysiological role of TNF in inflammation [66, 67], a basic phenomenon 
found in many diseases including SpA, and taking into account that anti-TNF therapy 
reaches often a great success in these patients [25-28], we asked for any potential 
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impact of TNFA genetics in SpA. A number of polymorphisms in the promoter of 
TNFA gene have been studied in different inflammatory and autoimmune diseases, 
including SpA [70-71, 83]. These polymorphisms might have a potential functional 
significance since they, by binding with different affinities transcription factors like 
OCT1 (Organic Cation Transporter 1) or NF-kB, up- or down-regulate mRNA 
transcription levels [70]. Five main TNFA promoter polymorphisms have been 
described in Caucasians, namely -1031T>C (rs1799964), -857C>T (rs1799724), -
376G>A (rs1800750), -308G>A (rs1800629), and -238G>A (rs361525) and among 
them association data with SpA have been reported with the 857C>T, -308G>A, and -
238G>A with contrastive results [71-83]. The opposite findings regarding these SNPs in 
SpA might be dependent on differences in ethnicity of the studied populations, in 
number of studied patients and on differences in selection criteria of patients and 
controls. Due to these uncertainty, in this study we verified whether these SNPs in 
addition to other two SNPs not previously investigated in depth, play a part in SpA 
alone or combined in haplotypes among them or with HLA-B27. Any single TNFA 
SNP was not associated with SpA diagnosis, nor with PsA or AS considered singly, and 
this is in agreement with previous data collected from a English AS population [81] as 
well as with data reported by Lee an co-workers in a meta-analysis [73]. This might 
mean that TNFA promoter polymorphisms do not play any role in predisposing to SpA 
disease or, otherwise, they may act only when combined in haplotypes. It is known, in 
fact, that the regulation of TNFA expression by transcription factors involve more than 
one single SNP, being the gene regulated by several transcription factors such as OCT1, 
NF-kB and AP1 (activator protein 1). The transcription factor OCT1 can strongly bind 
with the allele -857T (but not the -857C) thus blocking the interaction of NF-κB to the 
nearby region -873 to -863 leading to inhibition of TNF-α transcription. The 
transcription factor AP1 binds a region close to the -1031T>C SNP [70]. Based on these 
assumptions we evaluated by inferred statistical analysis the haplotypes deriving from 
the pairwise combinations of the five studied SNPs.  Due to the very low frequency of 
the -376A, -308A and -238A minor alleles (<0.1), the expected haplotypes including 
these alleles were almost completely absent in our population. Similarly the haplotype 
resulting from the combination of the minor alleles -1031C and -857T was very rare in 
our population despite a minor allele frequency for any single SNP higher than 0.2. We 
selected as a reference the most frequent haplotypes in controls and found that only the 
haplotype -1031C/-308G was significantly associated with SpA exerting in these 
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diseases a protective role, confirmed mainly in AS when any disease was considered 
singly. This finding might be explained taking into account that any single allele 
concurring in determining the studied haplotype was demonstrated to be associated with 
reduced TNF release. The -308G common allele was described to be associated with a 
lower spontaneous or stimulated TNF release both in vitro and in vivo with respect to 
the rare -308A allele [68, 147]. It is expected that the rare -1031C allele is also 
associated with low TNF production since it is in complete linkage disequilibrium with 
the -863A allele, which was demonstrated to be associated with reduced TNF release 
[148]. Therefore it may be assumed that low TNF producing alleles might exert effects 
on disease only when inherited together. To further verify the role of TNFA -1031/-308 
haplotype association with AS risk, we defined the resulting genotypes when possible 
and inferred them from haplotype frequencies in those cases that were heterozygotes for 
both SNPs. In agreement with the above reported observations, a higher frequency of 
TNFA -1031T/-308G homozygotes was found among AS cases than in controls or PsA, 
while the opposite was found considering subjects carrying the genotype combination 
of rare haplotypes.  
The above finding, however, should be evaluated taking into account also HLA-B27 
status, because of the nearby location of these genes. TNFA -1031T/-308G 
homozygotes were most frequent, while rare haplotypes were less frequently found 
among HLA-B27 carriers, suggesting the existence of an association between these two 
inherited conditions. 
We assumed that the risk effects on SpA exerted by TNFA and HLA-B27 might derive 
from their combination and to verify this assumption haplotypes were inferred. The 
frequency of haplotypes including HLA-B27 and the rare TNFA -376A, -308A and -
238A alleles was extremely low, so their association with SpA was not ascertainable. 
The two haplotypes resulting from the combination between HLA-B27 and TNFA-857 
C and T alleles were both associated with SpA considering patients overall. 
Interestingly the HLA-B27 positive/-857T haplotype was less frequent in AS than the 
HLA-B27 positive/-857C haplotype. Once again we hypothesize that a TNFA allele 
inhibiting TNF release, as the -857T allele, can antagonize inflammatory 
spondyloarthritis, this effect being evident when in the context of a powerful genetic 
predisposing factor like HLA-B27. 
In the complex scenario of TNF effects in inflammation and autoimmunity one might 
bear in mind the role of TNF receptors, which genetic variability might underlie 
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complex autoinflammatory diseases such as TRAPS [110, 111]. For this reason we 
evaluated whether sequence variations of the gene TNFRSF1A encoding for the TNFR1 
could be associated also with SpA. Only a few number of variants were detected in our 
population of patients and controls and none of them was associated with the diagnosis 
of AS or PsA. Therefore a role for TNFRSF1A genetics in SpA could be reasonably 
excluded. 
When considering the genetic predisposition to SpA, it was emerged in recent years 
from GWAS that HLA as well as non-HLA predisposing genes are involved and these 
include cytokines genes (e.g. IL23R, IL17, IL2R), but also genes encoding proteins of 
the inflammasome pathway (CARD9, CARD14, CARD16) [88-98]. This pathway is 
known to be critically involved in autoinflammatory diseases and genetic variants of 
MEFV gene, encoding for the protein pyrin, have recently been suggested as potentially 
involved also in SpA. This fits well with the relative frequent finding of SpA among 
patients with FMF [124-130]. In our study we identified several MEFV variants, half 
without functional significance and half with potential functional consequences for the 
predicted aminoacid substitution in the protein. These variants were however sporadic 
and none was associated with SpA diagnosis. Intriguingly the main MEFV variant that 
has been demonstrated to be associated with AS, namely the M694V [124-126], was 
never recorded among our patients. To explain this discrepant result we might take into 
consideration the followings: 
1. The association was described among Turkish population, which ethnicity is 
different from that of our patients; 
2. The selection criteria of the studied population are different: FMF diagnosis with 
a subsequent search for AS was the inclusion criterion for studies finding an 
association, while in our study the selection started from the presence of SpA;  
3. When an association between M694V and AS was found, all patients were 
invariably HLA-B27 negative, this further stressing the differences existing 
between our studied patients and other studied populations.  
One of the main problems in the clinical setting of SpA is dealing with 
interindividual variability in response to therapy, mainly in response to anti-TNFα 
agents [135-138, 149]. Different drugs belonging to this category are now available and 
they are frequently used to treat both AS and PsA especially when NSAIDs or 
DMARDS are not beneficial [36-38]. In our series about 80% AS and 50% PsA were on 
treatment with anti-TNFα drugs, and among them 13% AS and 25% PsA required in 
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their disease history the switch from one to at least another drug type for an incomplete 
response to treatment. This empirical approach is the only one actually proposed since 
no predictive response biomarkers are validated. Their identification is really necessary 
also considering the high costs for the health care system of this type of therapy [150]. 
Among factors that might affect variability in response to therapy, genetics should be 
considered besides to non-genetic physiological factors (age, sex, weight, and body fat), 
pathophysiological factors (liver, kidney, and cardiovascular function, and associated 
diseases), and environmental factors (tobacco and alcohol consumption and 
concomitant treatments) [139-143]. To enhance the challenge facing SpA treatment and 
variables that can predict response prior to treatment, we verified whether TNFA or 
TNFRSF1A genetics is involved. Patients were subdivided according to a reasonably 
prompt or delayed response to therapy by considering early responder those reaching a 
BASDAI ≤4 within 10 months and late responder those reaching the same goal after 10 
months from the starting therapy. The c.625+10A>G polymorphism of TNFRSF1A 
gene was associated with a different response to therapy, in particular carriers of the 
frequent A allele were mainly early responders, while those carrying the rare G allele 
were mainly late responders. The A allele was previously demonstrated to be correlated 
with increased serum TNF-α levels in patients with celiac disease [151] and an altered 
TNF-α/TNFR1 balance consequent to the synthesis of a truncated TNFR1 in patients 
carrying the rare G allele has been suggested by Ottoboni et al [152]. This 
polymorphism therefore might affect the response to anti-inflammatory therapy because 
of its potential effects on the TNF-TNFR pathway. When single drugs were evaluated 
with the aim to verify whether a difference exists between anti-TNF antibodies and anti-
TNF soluble receptors, we could only ascertain anti-TNF antibodies because in our 
series of patients only few cases were treated with etanercept. TNFRSF1A 
c.625+10A>G polymorphism was confirmed to influence the response to therapy in 
case of infliximab, but not in case of adalimumab treatment. This finding, if confirmed 
in larger series of patients, might support the use of adalimumab instead of infliximab, 
as first line therapy due to its efficacy independent from genetics.    
In conclusion the results of this study indicates the relevant role of TNF-TNFR 
pathway genetics in the complex network causing SpA and conditioning response to 
therapy. TNFA was shown to be a predisposing factor for SpA, but mainly for AS, 
among Italian patients, while genetics of the autoinflammatory gene MEFV appears of 
no impact in this setting. The haplotype resulting from TNFA-1031C/-308G, potentially 
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associated with lower TNF production, exerts a protective role in AS, while the 
TNFRSF1A c.625+10A>G polymorphism emerged as a potential predictor of response 
to anti- TNFα therapy.  
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